Antigen-binding molecules and uses thereof

JP2023550628A5Pending Publication Date: 2024-11-28SCOUT BIO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023530833
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-23
Filing Date
2021-11-22
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current therapeutic strategies for conditions associated with excessive interleukin-31 (IL-31) levels and activity, such as pruritus and atopic dermatitis, are inadequate and may cause adverse events, highlighting the need for improved antigen-binding molecules that specifically target IL-31 without losing binding specificity and selectivity.

Method used

Development of antigen-binding molecules with modified complementarity determining regions (CDRs) that specifically bind to IL-31, including IL-31 binding molecules that target unique regions of the IL-31 peptide sequence, such as amino acid positions 13, 15, 20, and 26, or avoid known binding regions, and are designed to minimize immune response in target species.

Benefits of technology

These molecules effectively neutralize IL-31 activity, providing therapeutic benefits for conditions like pruritus and atopic dermatitis while minimizing adverse reactions, and can be administered using vectors like AAV to ensure compatibility and efficacy across species.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure relates to an antigen-binding molecule that specifically binds to interleukin-31 (IL-31), the antigen-binding molecule comprising an immunoglobulin heavy chain variable domain and an immunoglobulin light chain variable domain. The present disclosure is based, at least in part, on an anti-IL-31 binding molecule that can specifically bind to native IL-31 and comprises complementarity-determining regions (CDRs) whose framework regions can be modified for compatibility with target species without losing binding specificity and selectivity for native IL-31.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related Applications This application claims priority to and the benefit of U.S. Provisional Application No. 63 / 117,383, filed November 23, 2020. The contents of the aforementioned patent application are incorporated herein by reference in their entirety.

[0002] FIELD OF THE INVENTION The present invention generally relates to antigen-binding molecules. In particular, the present invention relates to antigen-binding molecules that specifically bind to interleukin-31 (IL-31) and neutralize its activity, and their use for the treatment of conditions associated with abnormal IL-31 expression and / or activity, such as chronic inflammation, atopic dermatitis, eczema, pruritis, airway hyperresponsiveness, and inflammatory bowel syndrome.

[0003] Sequence Listing This application contains a Sequence Listing that has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. The ASCII copy, created on November 22, 2021, is titled "SCTB-012-01WO_SeqList_ST25.txt" and is 61KB in size. [Background technology]

[0004] background All references, including any patents or patent applications, cited in this specification are incorporated herein by reference to enable a complete understanding of the present invention. Nevertheless, such references should not be read as constituting an admission that any of these documents form part of the common general knowledge in the art in Australia or anywhere else.

[0005] As discussed by Sinem Bagci and Ruzicka (2018, J. Allergy Clin. Immunol.;141(3):858-866), IL-31 is a cytokine expressed in many human tissues and is involved in Th2-biased inflammatory responses. IL-31 signals through a receptor complex consisting of IL-31 receptor α and oncostatin M receptor β. Studies have shown that IL-31 is strongly associated with chronic pruritic skin disorders such as atopic eczema and is a novel target for directed drug therapy.

[0006] IL-31 belongs to the glycoprotein 130 (gp130) / IL-6 cytokine family, which also includes leukemia inhibitory factor, oncostatin M (OSM), cardiotrophin-1, ciliary neurotrophic factor, cardiotrophin-like cytokine, IL-6, and IL-11. Members of this family share the common gp130 chain in their multiunit receptors and are involved in immune regulation, including neuronal growth, bone metabolism, cardiac development, and T cell differentiation. In humans, the gene encoding IL-31 is located on chromosome 12q24.31 and consists of an open reading frame encoding a 164-amino acid precursor and a predicted 141-amino acid mature polypeptide containing a 4-α-helical structure. IL-31 has also been implicated in non-dermatological conditions, such as allergic asthma and rhinitis, inflammatory bowel disease, malignancies (e.g., cancer), and osteoporosis.

[0007] One of the first human trials investigating blockade of IL-31 signaling from a therapeutic perspective was conducted in healthy subjects and patients with atopic dermatitis using nemolizumab (CIM331), a humanized anti-human IL-31RA monoclonal antibody. This study showed that a single subcutaneous dose of nemolizumab significantly reduced visual analog scale (VAS) scores for pruritus and topical steroid use, as well as increased sleep efficiency. However, there were reports of adverse events, including worsening of atopic dermatitis and peripheral edema, particularly in patients receiving nemolizumab compared with patients receiving placebo. Thus, there remains an urgent need for improved therapeutic strategies for treating conditions associated with excessive IL-31 levels and / or activity, such as pruritus and other dermatological and non-dermatological conditions. [Prior art documents] [Non-patent literature]

[0008] [Non-Patent Document 1] Sinem Bagci and Ruzicka, 2018, J. Allergy Clin. Immunol.;141(3):858-866 Summary of the Invention [Means for solving the problem]

[0009] overview The present disclosure is based, at least in part, on anti-IL-31 binding molecules that contain complementarity-determining regions (CDRs) that can specifically bind to native IL-31 and whose framework regions can be modified for compatibility with target species without losing binding specificity and selectivity for native IL-31. Accordingly, the IL-31 binding molecules disclosed herein are suitable for use in the treatment and prevention of conditions associated with abnormal IL-31 levels and / or activity, examples of which include pruritus and atopic dermatitis.

[0010] Thus, in an embodiment disclosed herein, there is provided an antigen-binding molecule that specifically binds to interleukin-31 (IL-31), wherein the antigen-binding molecule comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein the VH comprises a complementarity-determining region 1 (VH CDR1) comprising the amino acid sequence of SEQ ID NO: 6, or an amino acid sequence having at least 80% sequence identity thereto, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 7, or an amino acid sequence having at least 80% sequence identity thereto, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 8, or an amino acid sequence having at least 80% sequence identity thereto; and the VL comprises a complementarity-determining region 1 (VL CDR1) comprising the amino acid sequence of SEQ ID NO: 9, or an amino acid sequence having at least 80% sequence identity thereto, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 10, or an amino acid sequence having at least 80% sequence identity thereto, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 11, or an amino acid sequence having at least 80% sequence identity thereto. and CDR3, wherein the amino acid sequences of the CDRs are based on the IMGT numbering system.

[0011] The present disclosure is also based, at least in part, on the inventor's discovery that the IL-31-binding molecules disclosed herein specifically bind to a region of canine IL-31 that has not been identified as the binding region of a known anti-IL-31 antibody molecule. Accordingly, in another aspect disclosed herein, there is provided an antigen-binding molecule that does not compete for binding to IL-31 with (i) an IL-31-binding molecule that specifically binds to a region of IL-31 corresponding to amino acid positions 13, 15, 20, and 26 of SEQ ID NO: 1, or (ii) an IL-31-binding molecule that specifically binds to a region of IL-31 corresponding to amino acid positions 76, 77, 80, 81, and 84 of SEQ ID NO: 1.

[0012] The present disclosure also extends to nucleic acid sequences encoding the antigen-binding molecules described herein, including the heavy and light chain sequences thereof and IL-31-binding fragments thereof.

[0013] Thus, in one aspect, there is provided an isolated nucleic acid molecule comprising a nucleic acid sequence encoding an antigen-binding molecule described herein.

[0014] Also disclosed herein are expression constructs comprising a nucleic acid sequence encoding the antigen-binding molecules described herein. The nucleic acid sequence may be operably linked to one or more regulatory sequences.

[0015] The present disclosure also extends to host cells containing the expression constructs described herein.

[0016] The present disclosure also extends to a vector comprising a nucleic acid sequence encoding the antigen-binding molecule described herein. In one embodiment, the vector is an AAV vector.

[0017] The present disclosure also extends to pharmaceutical compositions comprising the antigen-binding molecules described herein and a pharmaceutically acceptable carrier.

[0018] In another aspect disclosed herein, there is provided a method for treating or preventing a condition associated with increased expression and / or activity of IL-31, the method comprising administering to a subject in need thereof an antigen-binding molecule, vector, or pharmaceutical composition described herein.

[0019] The present disclosure also extends to kits comprising the antigen-binding molecules, vectors, or pharmaceutical compositions described herein.

[0020] In another aspect disclosed herein, there is provided use of an antigen-binding molecule or vector described herein in the manufacture of a medicament for treating or preventing a condition associated with increased expression and / or activity of IL-31 in a subject in need thereof.

[0021] The present disclosure also extends to an antigen-binding molecule, vector, or pharmaceutical composition described herein for use in treating or preventing a condition associated with increased expression and / or activity of IL-31 in a subject in need thereof.

[0022] The present disclosure also extends to an antigen-binding molecule, vector, or pharmaceutical composition described herein for use in treating or preventing tumors whose growth is induced by IL-31 and conditions associated therewith in a subject in need thereof.

[0023] The present disclosure also extends to antigen-binding molecules that specifically bind to an epitope of canine IL-31 comprising amino acid residues L29, Y32, Q33 and P40 of SEQ ID NO:1.

[0024] The present disclosure also extends to antigen-binding molecules that compete with the antigen-binding molecules described herein for binding to canine IL-31 of SEQ ID NO:1.

[0025] The present disclosure also extends to an immunogenic composition capable of eliciting an immune response against IL-31, the composition comprising: (i) an immunogen comprising a B cell epitope of IL-31; and (ii) a pharmaceutically acceptable carrier, wherein the B cell epitope comprises an amino acid sequence corresponding to amino acid positions 29-40 of SEQ ID NO: 1, or an amino acid sequence having at least 80% sequence identity thereto; and the immunogen does not comprise the amino acid sequence of a native IL-31 molecule. [Brief explanation of the drawings]

[0026] Embodiments of the present invention will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:

[0027] [Figure 1]Figure 1 shows the binding of RA4 to canine IL-31. Dose-response curve showing the binding of chimeric monoclonal antibody RA4 (chRA4) to canine IL-31 as determined by ELISA. Results shown are the absorbance ratio at 405 nm of specific binding over background.

[0028] [Figure 2] Figure 2 shows the inhibition of canine IL-31-induced STAT-3 phosphorylation in canine DH82 cells. Different concentrations of chRA4 monoclonal antibody were preincubated with canine IL-31 before addition to DH82 cells. These data indicate that RA4 can potently inhibit IL-31-induced STAT-3 phosphorylation in a dose-dependent manner. The observed IC50 was 1.5 μg / mL.

[0029] [Figure 3-1] Figure 3 shows the binding of anti-IL-31 antibodies chRA4, M14, and 34D03 to canine IL-31 (caIL-31), feline IL-31 (feIL-31), canine IL-31 variant 1, and canine IL-31 variant 2, as determined by ELISA. The data show that chimeric RA4 binds equally well to canine IL-31, feline IL-31, and two canine IL-31 variants (variants 1 and 2). M14 binds to canine IL-31 and canine IL-31 variant 1, but not to canine IL-31 variant 2. M14 binding to feline IL-31 was also reduced. 34D03 also binds to canine IL-31 and, to a lesser extent, feline IL-31, but did not bind to any of the canine IL-31 variant proteins. [Figure 3-2]Figure 3 shows the binding of anti-IL-31 antibodies chRA4, M14, and 34D03 to canine IL-31 (caIL-31), feline IL-31 (feIL-31), canine IL-31 variant 1, and canine IL-31 variant 2, as determined by ELISA. The data show that chimeric RA4 binds equally well to canine IL-31, feline IL-31, and two canine IL-31 variants (variants 1 and 2). M14 binds to canine IL-31 and canine IL-31 variant 1, but not to canine IL-31 variant 2. M14 binding to feline IL-31 was also reduced. 34D03 also binds to canine IL-31 and, to a lesser extent, feline IL-31, but did not bind to any of the canine IL-31 variant proteins.

[0030] [Figure 4] Figure 4A shows a schematic diagram of the canine / human chimeric proteins ca / huIL-31_c123_h4, cahuIL-31_c12_h34, and cahuIL-31_c1_h234. Figure 4B shows dose-response curves for monoclonal antibody RA4, which binds to canine IL-31 (caIL-31), human IL-31 (hIL-31), and chimeric canine / human IL-31 proteins (c123_h4, c12_h34, and c1_h234), as determined by ELISA.

[0031] [Figure 5A] FIG. 5A shows a schematic representation of a truncated series of overlapping peptides covering the N-terminal sequence of canine IL-31. [Figure 5B-1] Figure 5B shows the binding of RA4 and two previously described anti-IL-31 monoclonal antibodies, M14 and 34D03, to full-length canine IL-31 (Full ca IL-31) and overlapping peptides derived from the N-terminus of canine IL-31, as determined by ELISA. [Figure 5B-2]Figure 5B shows the binding of RA4 and two previously described anti-IL-31 monoclonal antibodies, M14 and 34D03, to full-length canine IL-31 (Full ca IL-31) and overlapping peptides derived from the N-terminus of canine IL-31, as determined by ELISA.

[0032] [Figure 6] Figure 6 shows the identification of residues in the N-terminal region of canine IL-31 that are important for RA4 mAb binding. An alanine scanning library of a 25 amino acid region of the N-terminal domain of canine IL-31 was generated. Binding of RA4 mAb to each of the modified (alanine-substituted) peptides was assessed by ELISA. Binding to each of the modified peptides was normalized to binding to the first peptide in the series relative to the left end of the X-axis (isoleucine).

[0033] [Figure 7] Figure 7 shows that RA4 mAb binds to a distinct, unique region at the N-terminus of canine IL-31. Full-length canine IL-31 proteins with either a single alanine substitution or a combination of all four alanine substitutions were used to assess binding of RA4 mAb (A) or M14 mAb (B) by ELISA. Wild-type canine IL-31 (caIL-31; SEQ ID NO: 1) was included as a control. DETAILED DESCRIPTION OF THE INVENTION

[0034] Detailed Description As described elsewhere herein, the present disclosure is based, at least in part, on anti-IL-31 binding molecules that can specifically bind to native IL-31 and that contain complementarity-determining regions (CDRs) whose framework regions can be modified for compatibility with target species without losing binding specificity and selectivity for native IL-31. Accordingly, the IL-31 binding molecules disclosed herein are suitable for use in the treatment and prevention of conditions associated with abnormal IL-31 levels and / or activity, examples of which include pruritus and atopic dermatitis.

[0035] Thus, disclosed herein is an antigen-binding molecule that specifically binds to interleukin-31 (IL-31), the antigen-binding molecule comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein the VH comprises a complementarity-determining region 1 (VH CDR1) comprising the amino acid sequence of SEQ ID NO: 6, or an amino acid sequence having at least 80% sequence identity thereto, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 7, or an amino acid sequence having at least 80% sequence identity thereto, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 8, or an amino acid sequence having at least 80% sequence identity thereto; the VL comprises a complementarity-determining region 1 (VL CDR1) comprising the amino acid sequence of SEQ ID NO: 9, or an amino acid sequence having at least 80% sequence identity thereto, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 10, or an amino acid sequence having at least 80% sequence identity thereto, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 11, or an amino acid sequence having at least 80% sequence identity thereto. It is an antigen-binding molecule comprising CDR3, and the amino acid sequences of the CDRs are based on the IMGT numbering system.

[0036] The CDR sequences disclosed herein are based on IMGT numbering unless otherwise specified.

[0037] The present disclosure is also based, at least in part, on the inventors' discovery that the IL-31-binding molecules disclosed herein specifically bind to a region of IL-31 that has not been identified for known IL-31-binding molecules. Accordingly, embodiments disclosed herein provide antigen-binding molecules that do not compete for binding to IL-31 with (i) an IL-31-binding molecule that specifically binds to a region of IL-31 corresponding to amino acid positions 13, 15, 20, and 26 of SEQ ID NO: 1, or (ii) an IL-31-binding molecule that specifically binds to a region of IL-31 corresponding to amino acid positions 76, 77, 80, 81, and 84 of SEQ ID NO: 1.

[0038] The term "corresponding to" refers to a region of an IL-31 peptide sequence that includes amino acid residues that, when aligned with the canine IL-31 peptide sequence of SEQ ID NO: 1, align with the residues of SEQ ID NO: 1. For example, a region of IL-31 corresponding to amino acid positions 13, 15, 20, and 26 of SEQ ID NO: 1 refers to a region of the IL-31 peptide sequence that includes amino acid residues that, when aligned with the canine IL-31 peptide sequence of SEQ ID NO: 1, align with the residues at positions 13, 15, 20, and 26 of SEQ ID NO: 1. Similarly, a region of IL-31 that corresponds to amino acid positions 76, 77, 80, 81, and 84 of SEQ ID NO: 1 refers to a region of the IL-31 peptide sequence that includes amino acid residues that, when aligned with the canine IL-31 peptide sequence of SEQ ID NO: 1, align with the residues at positions 76, 77, 80, 81, and 84 of SEQ ID NO: 1.

[0039] As described elsewhere herein, the present inventors have also found that the IL-31-binding molecules disclosed herein bind to an epitope of IL-31 comprising amino acid residues L29, Y32, Q33, and P40 of SEQ ID NO: 1. Thus, disclosed herein are antigen-binding molecules that specifically bind to an epitope of canine IL-31 comprising amino acid residues L29, Y32, Q33, and P40 of SEQ ID NO: 1.

[0040] The present disclosure also extends to antigen-binding molecules that compete with the antigen-binding molecules described herein for binding to canine IL-31 of SEQ ID NO:1.

[0041] As used herein, the term "compete" indicates that two or more antigen-binding molecules compete for binding to an antigen (e.g., IL-31). In one exemplary assay, IL-31 is coated on a solid substrate and allowed to bind to a first antigen-binding molecule, followed by the addition of a second antigen-binding molecule. If the presence of the first antigen-binding molecule reduces the binding of the second antigen-binding molecule to IL-31, the antigen-binding molecules are identified as competing for binding to IL-31. The term "compete" also includes combinations of antigen-binding molecules in which one antigen-binding molecule reduces the binding of another antigen-binding molecule, but no competition is observed when the antigen-binding molecules are added in the reverse order. However, in some embodiments, the first and second antigen-binding molecules inhibit each other's binding to the antigen, regardless of the order in which they are added. In one embodiment, one antigen-binding molecule reduces the binding of another antigen-binding molecule to an antigen by at least 20%, preferably at least 30%, preferably at least 40%, preferably at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%, or more preferably at least 95%.

[0042] As used herein, the term "antigen-binding molecule" refers to a molecule that has binding specificity for a target antigen. It is understood that this term extends to immunoglobulins, immunoglobulin fragments, and non-immunoglobulin-derived protein frameworks that exhibit antigen-binding activity. Examples of suitable antigen-binding molecules include antibodies and antigen-binding fragments thereof. Preferably, the antigen-binding molecule specifically binds to IL-31 in a manner that neutralizes or substantially neutralizes its activity. The term "neutralizing" is understood to mean that the antigen-binding molecule binds to IL-31 and inhibits, reduces, abrogates, blocks, or otherwise prevents the ability of the IL-31 molecule to bind to its natural receptor. In some embodiments, the antigen-binding molecule completely neutralizes the activity of IL-31 (in vivo or in vitro), such that IL-31 activity is absent or negligible compared to the absence of the antigen-binding molecule. In other embodiments, the antigen-binding molecule partially neutralizes the activity of IL-31 (in vivo or in vitro), such that IL-31 activity is reduced compared to the absence of the antigen-binding molecule.

[0043] As used herein, the term "antibody" is understood to mean any antigen-binding molecule or molecular complex that contains at least one complementarity-determining region (CDR) that specifically binds to or interacts specifically with a target antigen. The term "antibody" includes full-length immunoglobulin molecules containing two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, as well as multimers thereof (e.g., IgM). Each heavy chain contains a heavy chain variable region (HCVR, VH, or V). H The heavy chain constant region typically comprises three domains - C H 1. C H 2 and C H Each light chain contains a light chain variable region (LCVR, VL, VK, V K or V L The light chain constant region typically comprises one domain (C L 1) V H and V LThe V region can be further subdivided into regions of hypervariability, called complementarity-determining regions (CDRs), interspersed with more conserved regions, also called framework regions (FRs). H and V L Typically, the antigen-binding molecule or antigen-binding fragment thereof comprises three CDRs and four FRs arranged in the following order from the amino terminus to the carboxy terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In some embodiments, the FRs of the antigen-binding molecules described herein may be identical to the FRs of the germline sequence of the target species (i.e., the species to which the antigen-binding molecules or antigen-binding fragments thereof described herein are administered). In some embodiments, the FRs may be naturally or artificially modified. While it is generally desirable that each of the FR sequences be identical to the FR sequences derived from an immunoglobulin molecule of the target species, including minimizing the immune response elicited against the binding molecule upon administration to a subject of the target species, in some embodiments, the antigen-binding molecule or antigen-binding fragment thereof may comprise one or more amino acid residues across one or more of its FR sequences that may be foreign at corresponding positions in one or more FRs from the target species. Preferably, when an antigen-binding molecule or antigen-binding fragment thereof comprises, across one or more of its FR sequences, one or more amino acid residues that are foreign at corresponding positions in the target species, the "foreign" amino acid residues (i) do not adversely affect the binding specificity of the antigen-binding molecule or antigen-binding fragment thereof for IL-31, including native IL-31, and / or (ii) do not elicit an immune response against the antigen-binding molecule or antigen-binding fragment thereof when administered to a subject of the target species.

[0044] Suitable antibodies include canine IgGA, IgGB, IgGC, and IgGD, and feline IgG1a, IgG1b, and IgG2, including their subclasses. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known to those skilled in the art.

[0045] As used herein, the term "complementarity-determining region" (CDR) refers to the region of an immunoglobulin variable domain that recognizes and binds to a target antigen. Each variable domain may contain up to three CDR sequences, identified as CDR1, CDR2, and CDR3. The amino acid sequence of each CDR may be expressed according to Kabat numbering (e.g., about residues 24-34 (L1), 50-56 (L2), and 89-97 (L3) of the light chain variable domain and residues 31-35 (H1), 50-65 (H2), and 95-102 (H3) of the heavy chain variable domain; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)) and / or Chothia numbering (e.g., Chothia and Lesk for residues 26-32 (L1), 50-52 (L2), and 91-96 (L3) of the light chain variable domain and residues 26-32 (H1), 53-55 (H2), and 96-101 (H3) of the heavy chain variable domain). J. Mol. Biol. 196:901-917 (1987)). The CDR sequences disclosed herein are based on the IMGT numbering system unless otherwise specified.

[0046] In one embodiment, the antigen-binding molecules described herein are conjugated to another molecule or moiety, including functional moieties (e.g., toxins), detectable moieties (e.g., fluorescent molecules, radioisotopes), small molecule drugs, and polypeptides.

[0047] It should be understood that modifications can be made to the antigen-binding molecules described herein, including CDR sequences, without adversely affecting the binding specificity of the antigen-binding molecules described herein. Accordingly, the present disclosure also extends to functional variants of the IL-31-binding molecules disclosed herein. The term "functional variant" as used herein should be understood to mean an IL-31-binding molecule that comprises an amino acid sequence that differs from a parent sequence or a comparable sequence (e.g., VH and / or VL) by one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16, 17, 18, 19, 20, 21, etc.) amino acid deletions, insertions, and / or substitutions, wherein the differences do not abolish or completely abolish the ability of the variant to bind to IL-31.

[0048] Suitable methods for determining whether a variant retains the above-described function are well known to those skilled in the art, and examples are described elsewhere herein. A functional variant may comprise an amino acid sequence that differs from a comparator sequence (e.g., SEQ ID NOs: 12 and 13). In some embodiments, a functional variant may comprise an amino acid substitution that enhances the binding affinity of the antigen-binding molecule to IL-31 compared to a reference molecule to which the variant is compared (e.g., an antigen-binding molecule comprising a VH and VL or SEQ ID NOs: 12 and 13). In one embodiment, a functional variant differs from a comparator by one or more conservative amino acid substitutions, as described elsewhere herein.

[0049] Reference to "at least 80% sequence identity" includes 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a reference sequence (e.g., any one of SEQ ID NOs: 6-13), for example, after optimal alignment or best fit analysis. Thus, in one embodiment, a functional variant of an antigen-binding molecule comprises, consists of, or essentially consists of an amino acid sequence having at least 80%, preferably at least 85%, preferably at least 86%, preferably at least 87%, preferably at least 88%, preferably at least 89%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, preferably at least 99%, or preferably 100% sequence identity with SEQ ID NO: 12 or SEQ ID NO: 13, for example, after optimal alignment or best fit analysis. In another embodiment, the CDR sequence of the functional variant of the antigen-binding molecule comprises, consists of, or essentially consists of an amino acid sequence having at least 80%, preferably at least 85%, preferably at least 86%, preferably at least 87%, preferably at least 88%, preferably at least 89%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, preferably at least 99%, or preferably 100% sequence identity to any one of SEQ ID NOs: 6 to 11, for example, after optimal alignment or best fit analysis.

[0050] In one embodiment, (i) the VH comprises a complementarity determining region 1 (VH) comprising an amino acid sequence having at least 80%, preferably at least 85%, preferably at least 86%, preferably at least 87%, preferably at least 88%, preferably at least 89%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, preferably at least 99% or preferably 100% sequence identity to SEQ ID NO: 6. a VH CDR1) comprising an amino acid sequence having at least 80%, preferably at least 85%, preferably at least 86%, preferably at least 87%, preferably at least 88%, preferably at least 89%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, preferably at least 99% or preferably 100% sequence identity to SEQ ID NO: 7, and a VH CDR3 comprising an amino acid sequence having at least 80%, preferably at least 85%, preferably at least 86%, preferably at least 87%, preferably at least 88%, preferably at least 89%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, preferably at least 99% or preferably 100% sequence identity to SEQ ID NO: 8;(ii) VL comprises a complementarity determining region 1 (VL) comprising an amino acid sequence having at least 80%, preferably at least 85%, preferably at least 86%, preferably at least 87%, preferably at least 88%, preferably at least 89%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, preferably at least 99%, or preferably 100% sequence identity to SEQ ID NO: 9. and a VL CDR1) comprising an amino acid sequence having at least 80%, preferably at least 85%, preferably at least 86%, preferably at least 87%, preferably at least 88%, preferably at least 89%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, preferably at least 99% or preferably 100% sequence identity to SEQ ID NO: 10; and a VL CDR3 comprising an amino acid sequence having at least 80%, preferably at least 85%, preferably at least 86%, preferably at least 87%, preferably at least 88%, preferably at least 89%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, preferably at least 99% or preferably 100% sequence identity to SEQ ID NO: 11. ;

[0051] In one embodiment, the VH comprises a complementarity determining region 1 (VH CDR1) comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 6, a VH CDR2 comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 7, and a VH CDR3 comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 8; and the VL comprises a complementarity determining region 1 (VL CDR1) comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 9, a VL CDR2 comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 10, and a VL CDR3 comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 11.

[0052] In one embodiment, the VH comprises a complementarity determining region 1 (VH CDR1) comprising, consisting of, or consisting essentially of the amino acid sequence of SEQ ID NO: 6, a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence of SEQ ID NO: 7, and a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence of SEQ ID NO: 8; and the VL comprises, consisting of, or essentially consists of a complementarity determining region 1 (VL CDR1) comprising, consisting of, or consisting essentially of the amino acid sequence of SEQ ID NO: 9, a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence of SEQ ID NO: 10, and a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence of SEQ ID NO: 11.

[0053] In one embodiment, the antigen-binding molecule described herein comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 12, or an amino acid sequence having at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 95%, or more preferably at least 98% sequence identity thereto. In one embodiment, the antigen-binding molecule described herein comprises a light chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 13, or an amino acid sequence having at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 95%, or more preferably at least 98% sequence identity thereto.

[0054] In one embodiment, the antigen-binding molecule described herein comprises (a) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 12, or an amino acid sequence having at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 95%, or more preferably at least 98% sequence identity thereto; and (b) a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 13, or an amino acid sequence having at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 95%, or more preferably at least 98% sequence identity thereto.

[0055] In one embodiment, the antigen-binding molecule described herein comprises (a) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 12, or an amino acid sequence having at least 80% sequence identity thereto; and (b) a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 13, or an amino acid sequence having at least 80% sequence identity thereto.

[0056] In one embodiment, the heavy chain variable region (VH) comprises the amino acid sequence of SEQ ID NO:12 and the light chain variable region (VL) comprises the amino acid sequence of SEQ ID NO:13.

[0057] In one embodiment, the heavy chain variable region (VH) consists of or consists essentially of the amino acid sequence of SEQ ID NO: 12, and the light chain variable region (VL) consists of or consists essentially of the amino acid sequence of SEQ ID NO: 13.

[0058] As used herein, the terms "identity," "similarity," "sequence identity," "sequence similarity," "homology," "sequence homology," and the like refer to the fact that at any particular amino acid residue position in the aligned sequences, the amino acid residue is identical between the aligned sequences. As used herein, the term "similarity" or "sequence similarity" indicates that at any particular position in the aligned sequences, the amino acid residue is of a similar type between the sequences. For example, leucine may be used in place of an isoleucine or valine residue. This may be referred to as a conservative substitution. In one embodiment, an amino acid sequence may be modified by conservative substitution of any of the amino acid residues contained therein, such that the modification does not affect the binding specificity or functional activity of the modified polypeptide compared to the unmodified polypeptide.

[0059] In some embodiments, sequence identity for a peptide sequence refers to the percentage of amino acid residues in a candidate sequence that are identical to the residues of the corresponding peptide sequence, after aligning the sequences and introducing gaps as necessary to achieve the maximum percentage homology, without considering conservative substitutions as part of the sequence identity.Neither N-terminal nor C-terminal extensions nor insertions should be interpreted as reducing sequence identity or homology.Methods and computer programs for aligning two or more amino acid sequences and determining their sequence identity or homology are well known to those skilled in the art.For example, the percentage identity or similarity of two amino acid sequences can be easily calculated using algorithms such as BLAST, FASTA, or Smith-Waterman algorithms.

[0060] Techniques for determining amino acid sequence "similarity" are well known to those skilled in the art. Generally, "similarity" refers to an exact amino acid-to-amino acid comparison of two or more peptide sequences, or where appropriate, where the amino acids are identical or have similar chemical and / or physical properties, such as charge or hydrophobicity. In that case, a so-called "percent similarity" can be determined between the compared peptide sequences. Generally, "identity" refers to an exact amino acid-to-amino acid correspondence of the two peptide sequences.

[0061] Two or more peptide sequences can also be compared by determining their "percent identity." The percent identity of two sequences can be expressed as the number of exact matches between two aligned sequences divided by the length of the shorter sequence multiplied by 100. Approximate alignment of nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2:482-489 (1981). This algorithm can be extended for use with peptide sequences using a scoring matrix developed by Dayhoff, Atlas of Protein Sequences and Structure, MO Dayhoff ed., 5 suppl. 3:353-358, National Biomedical Research Foundation, Washington, DC, USA, and standardized by Gribskov, Nucl. Acids Res. 14(6):6745-6763 (1986). Suitable programs for calculating percent identity or similarity between sequences are generally known in the art.

[0062] Optimal alignment of sequences for aligning a comparison window can be performed by computerized implementation of algorithms (GAP, BESTFIT, FASTA, and TFASTA from Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive, Madison, WI, USA) or by examining and selecting the best alignment (i.e., the one that results in the highest percentage of homology across the comparison window) generated by any of the various methods. For example, the BLAST family of programs disclosed by Altschul et al., 1997, Nucl. Acids Res. 25:3389 can also be used. A detailed discussion of sequence analysis can be found in Unit 19.3 of Chapter 15 in Ausubel et al., "Current Protocols in Molecular Biology," John Wiley & Sons Inc., 1994-1998.

[0063] In some embodiments, functional variants comprise at least one (e.g., 1, 2, 3, 4, or 5) amino acid substitution, preferably a conservative amino acid substitution, in any one or more of the CDR sequences. In one embodiment, the antigen-binding molecule comprises one, two, or three amino acid substitutions in any one or more of the CDR sequences. In other embodiments, functional variants comprise one or more amino acid substitutions, insertions, and / or deletions in non-CDR regions (e.g., framework regions) of the VH and / or VL sequences.

[0064] Screening and identifying functional variants capable of specifically binding to IL-31 is well within the capabilities of one of ordinary skill in the art. Illustrative examples of suitable screening methods are described elsewhere herein.

[0065] In a preferred embodiment, the amino acid substitution is a conservative amino acid substitution. A "conservative amino acid substitution" should be understood to mean a substitution in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art and can be generally subclassified as shown in the table below, "Amino Acid Classifications." [Table 4]

[0066] Conservative amino acid substitution also includes grouping based on side chain.For example, the group of amino acids with aliphatic side chains is glycine, alanine, valine, leucine and isoleucine; the group of amino acids with aliphatic-hydroxyl side chains is serine and threonine; the group of amino acids with amide-containing side chains is asparagine and glutamine; the group of amino acids with aromatic side chains is phenylalanine, tyrosine and tryptophan; the group of amino acids with basic side chains is lysine, arginine and histidine; the group of amino acids with sulfur-containing side chains is cysteine ​​and methionine.For example, it is reasonable to expect that replacing leucine with isoleucine or valine, replacing aspartic acid with glutamic acid, replacing threonine with serine, or similarly replacing amino acids with structurally related amino acids will not significantly affect the properties of the resulting variant polypeptide.Whether amino acid change results in functional polypeptide can be easily determined by assaying its activity.

[0067] Conservative substitutions are also shown in the table below (exemplary and preferred amino acid substitutions). Amino acid substitutions that fall within the scope of the invention are generally achieved by selecting substitutions that do not significantly differ in their effect on (a) the structure of the peptide backbone in the area of ​​the substitution, (b) the charge or hydrophobicity of the molecule at the target site, or (c) maintaining the bulk of the side chain. After substitutions are introduced, variants can be screened for their ability to specifically bind to IL-31 using methods known to those of skill in the art, including those described elsewhere herein. [Table 5]

[0068] In one embodiment, the antigen binding molecules described herein specifically bind to canine IL-31. In one embodiment, the antigen binding molecules described herein specifically bind to feline IL-31.

[0069] The present disclosure extends to antigen-binding molecules that specifically bind to native IL-31 (i.e., naturally occurring IL-31), as well as variants thereof. Such variants may include IL-31 molecules that differ from naturally occurring (wild-type) molecules by one or more amino acid substitutions, deletions, and / or insertions. Variant IL-31 molecules of this type may be in naturally occurring or synthetic (e.g., recombinant) form. However, it should be understood that in preferred embodiments, the antigen-binding molecules described herein specifically bind to the native form of IL-31.

[0070] The terms "antigen-binding fragment," "antigen-binding portion," "antigen-binding domain," "antigen-binding site," and the like are used interchangeably herein to refer to a portion of an antigen-binding molecule that retains the ability to bind to a target antigen (i.e., IL-31, including native IL-31). These terms include naturally occurring, enzymatically obtainable, synthetic, or genetically engineered (recombinant) polypeptides and glycoproteins that specifically bind to IL-31 to form a complex.

[0071] Antigen-binding fragments can be obtained, for example, from naturally occurring immunoglobulin molecules using any suitable method known to those of skill in the art, examples of which include proteolytic digestion or recombinant genetic engineering techniques, including the manipulation and expression of nucleic acid sequences encoding antibody variable domains and, optionally, constant domains. Suitable nucleic acid sequences are known and / or readily available, for example, from commercial sources, DNA libraries (including, for example, phage antibody libraries), or can be synthesized. Nucleic acid sequences can be sequenced and manipulated, for example, chemically or using molecular biology techniques, to arrange one or more variable and / or constant domains in the appropriate configuration, or to introduce codons, create cysteine ​​residues, modify, add, or delete amino acids, etc.

[0072] Non-limiting examples of suitable antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of amino acid residues mimicking the hypervariable regions of an antibody (e.g., isolated CDRs, e.g., CDR3 peptides) or constrained FR3-CDR3-FR4 peptides. Other engineered molecules, such as domain-specific antibodies, single-domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, one-arm antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), and small modular immunopharmaceuticals (SMIPs), are also encompassed by the term "antigen-binding fragment" as used herein.

[0073] In one embodiment, the antigen-binding fragment comprises at least one immunoglobulin variable domain. The variable domain may comprise an amino acid sequence of any suitable length or composition, and generally comprises at least one CDR adjacent to or in-frame with one or more framework sequences. H Domains and V L If it contains a domain, VH Domains and V L The domains can be positioned relative to each other in any suitable arrangement. For example, the variable region can be a dimer, with the V H -V H , V H -V L or V L -V L Alternatively, the antigen-binding fragment of an antibody may contain a dimer of monomeric V H or V L It may contain domains.

[0074] In some embodiments, an antigen-binding fragment may comprise at least one variable domain covalently linked to at least one constant domain. Non-limiting configurations of variable and constant domains that may be found in an antigen-binding fragment include: (i) V H -C H 1;(ii)V H -C H 2;(iii)V H -C H 3;(iv)V H -C H 1-C H 2;(v)V H -C H 1-C H 2-C H 3. (vi) V H -C H 2-C H 3;(vii)V H -C L ;(viii)V L -C H 1;(ix)V L -C H 2. (x)V L -C H 3;(xi)V L -C H 1-C H 2;(xii)V L -C H 1-C H 2-C H 3;(xiii)V L -C H 2-C H 3; and (xiv) VL -C L In any configuration of variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains may be directly linked to each other or may be linked by a complete or partial hinge or linker region. The hinge region may consist of at least two (e.g., 5, 10, 15, 20, 40, 60, or more) amino acids that provide a flexible or semi-flexible linkage between adjacent variable and / or constant domains within a single polypeptide molecule. In some embodiments, the antigen-binding fragments described herein are linked to each other and / or to one or more monomeric V H or V L The variable domain and constant domain may comprise homodimers or heterodimers (or other multimers) of any of the above-listed variable domain and constant domain configurations non-covalently associated (e.g., via disulfide bond(s)). Multispecific antigen-binding molecules typically comprise at least two different variable domains, each capable of specifically binding to a distinct antigen or a different epitope on the same antigen. Any multispecific antigen-binding molecule format, including bispecific antigen-binding molecule formats, can be adapted for use in the context of the antigen-binding fragments of antibodies of the present disclosure using routine techniques available in the art.

[0075] The term "variable region" or "variable domain" refers to the domain of an immunoglobulin heavy or light chain that is involved in binding to a target antigen. The variable domains of the heavy and light chains (V, respectively) of a naturally occurring immunoglobulin molecule H and V L ) generally have a similar structure, with each domain containing four conserved framework regions and three hypervariable regions (HVRs). See, e.g., Kindt et al., Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007). A single V H or V L The domain may be sufficient to confer antigen-binding specificity.

[0076] The antigen-binding molecules described herein may be appropriately modified for compatibility with the target species, for example, to minimize or otherwise avoid an immune response generated against the antigen-binding molecule after administration to that species. In one embodiment, the antigen-binding molecule is caninized, felinized, or equineized.

[0077] "Caninized" means that the antigen-binding molecule comprises an amino acid sequence that is compatible with dogs, such that the amino acid sequence is unlikely to be regarded as foreign by the immune system of a canine subject. In one embodiment, the caninized antigen-binding molecule comprises one or more immunoglobulin framework regions derived from one or more canine immunoglobulin molecules. In some embodiments, all of the framework regions of the caninized antigen-binding molecule are derived from one or more canine immunoglobulin molecules. The caninized antibody may optionally comprise an immunoglobulin heavy chain constant region derived from a canine immunoglobulin molecule. Thus, in one embodiment, the antigen-binding molecule is a caninized antigen-binding molecule.

[0078] "Fenconized" means that the antigen-binding molecule comprises an amino acid sequence that is compatible with felines, such that the amino acid sequence is unlikely to be regarded as foreign by the immune system of a feline subject. In one embodiment, the felined antigen-binding molecule comprises one or more immunoglobulin framework regions derived from one or more feline immunoglobulin molecules. In some embodiments, all of the framework regions of the felined antigen-binding molecule are derived from one or more feline immunoglobulin molecules. The felined antibody may optionally comprise an immunoglobulin heavy chain constant region derived from a feline immunoglobulin molecule. In one embodiment, the antigen-binding molecule is a felined antigen-binding molecule.

[0079] "Equine-ized" means that the antigen-binding molecule comprises an amino acid sequence that is compatible with horses, such that the amino acid sequence is unlikely to be regarded as foreign by the immune system of an equine subject. In one embodiment, the equine-ized antigen-binding molecule comprises one or more immunoglobulin framework regions derived from one or more equine immunoglobulin molecules. In some embodiments, all of the framework regions of the equine-ized antigen-binding molecule are derived from one or more equine immunoglobulin molecules. The equine-ized antibody may optionally comprise an immunoglobulin heavy chain constant region derived from an equine immunoglobulin molecule.

[0080] It should be understood that the present disclosure also extends to antigen-binding molecules that are compatible with species other than dogs, cats, and horses. In this regard, antigen-binding molecules may be referred to as "speciesized," referring to the target species to which the molecule is administered.

[0081] Suitable methods for designing and producing recombinant antibodies or antigen-binding molecules compatible with a target species are well known to those skilled in the art, examples of which are described in Cattaneo (2010; Curr. Op. Mol. Ther. 12(1):94-106), WO2006 / 131951, WO2012 / 153122, WO2013 / 034900, WO2012 / 153121 and WO2012 / 153123, the contents of which are incorporated herein by reference in their entirety.

[0082] In one embodiment, the antigen-binding molecule is caninized. In one embodiment, the caninized antigen-binding molecule comprises (i) a heavy chain variable domain (VH) comprising: (a) a heavy chain variable domain framework region 1 (VHFR1) amino acid sequence having at least 80% sequence identity to a VHFR1 amino acid sequence selected from the group consisting of SEQ ID NOs: 18, 22, 26, 30, and 34; (b) a VHFR2 amino acid sequence having at least 80% sequence identity to a VHFR2 amino acid sequence selected from the group consisting of SEQ ID NOs: 19, 23, 27, 31, and 35; (c) a VHFR3 amino acid sequence having at least 80% sequence identity to a VHFR3 amino acid sequence selected from the group consisting of SEQ ID NOs: 20, 24, 27, 32, and 36; and (d) a VHFR4 amino acid sequence having at least 80% sequence identity to a VHFR4 amino acid sequence selected from the group consisting of SEQ ID NOs: 21, 25, 28, 33, and 37; and / or (ii) a light chain variable domain (VL) comprising: (e) a heavy chain variable domain framework region 1 (VLFR1) amino acid sequence having at least 80% sequence identity to a VLFR1 amino acid sequence selected from the group consisting of SEQ ID NOs: 38, 42, 46, and 50; (f) a VLFR2 amino acid sequence having at least 80% sequence identity to a VLFR2 amino acid sequence selected from the group consisting of SEQ ID NOs: 39, 43, 47, and 51; (g) a VLFR3 amino acid sequence having at least 80% sequence identity to a VLFR3 amino acid sequence selected from the group consisting of SEQ ID NOs: 40, 44, 48, and 52; (h) a VLFR4 amino acid sequence having at least 80% sequence identity to a VHFR4 amino acid sequence selected from the group consisting of SEQ ID NOs: 41, 45, 49, and 53. Includes:

[0083] In one embodiment, the caninized antigen-binding molecule is (i) a heavy chain variable domain (VH) comprising: (a) a heavy chain variable domain framework region 1 (VHFR1) amino acid sequence having at least 80% sequence identity to the VHFR1 amino acid sequence of SEQ ID NO: 81 or SEQ ID NO: 85; (b) a VHFR2 amino acid sequence having at least 80% sequence identity to the VHFR2 amino acid sequence of SEQ ID NO: 82 or SEQ ID NO: 86; (c) a VHFR3 amino acid sequence having at least 80% sequence identity to the VHFR3 amino acid sequence of SEQ ID NO: 83 or SEQ ID NO: 87, and (d) a VHFR4 amino acid sequence having at least 80% sequence identity to the VHFR4 amino acid sequence of SEQ ID NO: 84 or SEQ ID NO: 88; and / or (ii) a light chain variable domain (VL) comprising: (e) a heavy chain variable domain framework region 1 (VLFR1) amino acid sequence having at least 80% sequence identity to the VLFR1 amino acid sequence of SEQ ID NO: 89; (f) a VLFR2 amino acid sequence having at least 80% sequence identity to the VLFR2 amino acid sequence of SEQ ID NO: 90; (g) a VLFR3 amino acid sequence having at least 80% sequence identity to the VLFR3 amino acid sequence of SEQ ID NO: 91; and (h) a VLFR4 amino acid sequence having at least 80% sequence identity to the VHFR4 amino acid sequence of SEQ ID NO: 92 Includes:

[0084] In one embodiment, the caninized antigen binding molecule comprises a heavy chain variable domain (VH) comprising an amino acid sequence having at least 80% sequence identity to the VH amino acid sequence of SEQ ID NO:99 or SEQ ID NO:100.

[0085] In one embodiment, the caninized antigen binding molecule comprises a light chain variable domain (VL) comprising an amino acid sequence having at least 80% sequence identity to the VL amino acid sequence of SEQ ID NO:101.

[0086] In one embodiment, the antigen-binding molecule is felinized. In one embodiment, the felinized antigen-binding molecule comprises (i) a heavy chain variable domain (VH) comprising: (a) a heavy chain variable domain framework region 1 (VHFR1) amino acid sequence having at least 80% sequence identity to the VHFR1 amino acid sequence of SEQ ID NO: 54; (b) a VHFR2 amino acid sequence having at least 80% sequence identity to the VHFR2 amino acid sequence of SEQ ID NO: 55; (c) a VHFR3 amino acid sequence having at least 80% sequence identity to the VHFR3 amino acid sequence of SEQ ID NO: 56, and (d) a VHFR4 amino acid sequence having at least 80% sequence identity to the VHFR4 amino acid sequence of SEQ ID NO: 57; and / or (ii) a light chain variable domain (VL) comprising: (e) a light chain variable domain framework region 1 (VLFR1) amino acid sequence having at least 80% sequence identity to the VLFR1 amino acid sequence of SEQ ID NO: 58; (f) a VLFR2 amino acid sequence having at least 80% sequence identity to the VLFR2 amino acid sequence of SEQ ID NO: 59; (g) a VLFR3 amino acid sequence having at least 80% sequence identity to the VLFR3 amino acid sequence of SEQ ID NO: 60; and (h) a VLFR4 amino acid sequence having at least 80% sequence identity to the VHFR4 amino acid sequence of SEQ ID NO: 61 Includes:

[0087] Other suitable framework region sequences that can be used to modify the antigen-binding molecules disclosed herein for compatibility with target species, including dogs, cats, and horses, are well known to those skilled in the art, and examples are described in Cattaneo (2010; supra), WO2006 / 131951, WO2012 / 153122, WO2013 / 034900, WO2012 / 153121, and WO2012 / 153123.

[0088] The phrases "specifically bind" or "specific binding" refer to a binding reaction between two molecules that is at least twice background, and more typically 10- to 100-fold greater than background molecular association, under physiological conditions. When one or more detectable binding agents that are proteins are used, specific binding determines the presence of the protein in a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, a designated antigen-binding molecule binds to a specific antigenic determinant, thereby identifying its presence. Specific binding to an antigenic determinant under such conditions requires an antigen-binding molecule selected for its specificity for that determinant. This selection can be achieved by subtracting antigen-binding molecules that cross-react with other molecules. Various immunoassay formats can be used to select antigen-binding molecules (e.g., immunoglobulins) that are specifically immunoreactive with a particular antigen. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual (1988) for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity). Methods for determining binding affinity and specificity are also well known in the art (see, e.g., Harlow and Lane, supra; Friefelder, "Physical Biochemistry: Applications to biochemistry and molecular biology" (WH Freeman and Co. 1976)).

[0089] "Affinity" or "binding affinity" refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antigen-binding molecule) and its binding partner (e.g., an antigen). Unless otherwise specified, as used herein, "binding affinity" refers to the intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair, e.g., an antigen-binding molecule. The affinity of a molecule X for its partner Y is generally determined by the ratio of the dissociation rate constant to the association rate constant (koff and k on The affinity can be expressed by a dissociation constant (Kd), which is the dissociation constant (Kd) of the affinity molecule. Therefore, equivalent affinities may include different rate constants, as long as the ratio of the rate constants remains the same. Affinity can be measured by common methods known in the art, including those described herein. A particular method for measuring affinity is surface plasmon resonance (SPR).

[0090] The terms "polypeptide," "peptide," or "protein" are used interchangeably herein to refer to a linear series of amino acid residues joined together by peptide bonds between the alpha-amino and carboxy groups of adjacent residues. The amino acid residues are normally in the naturally occurring "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, so long as the desired functional property is retained by the polypeptide.

[0091] As used herein, the term "modified antibody" includes synthetic forms of antibodies that have been modified so that they do not occur in nature, such as antibodies that contain at least two heavy chain portions but not two complete heavy chains (such as domain-deleted antibodies or minibodies); multispecific forms of antibodies (e.g., bispecific, trispecific, etc.) that have been modified to bind to two or more different antigens or different epitopes on a single antigen; heavy chain molecules combined into scFv molecules; and the like. scFv molecules are known in the art and are described, for example, in U.S. Pat. No. 5,892,019. Furthermore, the term "modified antibody" includes multivalent forms of antibodies (e.g., trivalent, tetravalent, etc., antibodies that bind to three or more copies of the same antigen).

[0092] In one embodiment, the antigen-binding molecule is an antibody or antigen-binding fragment thereof, as described elsewhere herein. In one embodiment, the antigen-binding fragment is selected from the group consisting of a Fab fragment, an scFab, an Fab', a single-chain variable fragment (scFv), and a one-arm antibody.

[0093] In one embodiment, the antigen-binding molecule comprises the heavy and / or light chain constant regions of an immunoglobulin molecule, hi one embodiment, the antigen-binding molecule comprises the heavy and / or light chain constant regions of a canine, feline, or equine immunoglobulin molecule.

[0094] In one embodiment, the antigen-binding molecule comprises a heavy chain constant region of a canine immunoglobulin molecule. In one embodiment, the antigen-binding molecule comprises a light chain constant region of a canine immunoglobulin molecule. In a further embodiment, the antigen-binding molecule comprises both heavy and light chain constant regions of a canine immunoglobulin molecule.

[0095] In one embodiment, the antigen-binding molecule comprises a heavy chain constant region of a canine immunoglobulin molecule selected from the group consisting of IgGA, IgGB, IgGC, and IgGD. In one embodiment, the antigen-binding molecule comprises a light chain constant region of a canine immunoglobulin molecule selected from the group consisting of IgGA, IgGB, IgGC, and IgGD. In one embodiment, the antigen-binding molecule comprises a heavy chain constant region and a light chain constant region of a canine immunoglobulin molecule selected from the group consisting of IgGA, IgGB, IgGC, and IgGD.

[0096] In one embodiment, the antigen-binding molecule comprises the heavy chain constant region of a canine IgGA molecule. In one embodiment, the antigen-binding molecule comprises the light chain constant region of a canine IgGA molecule. In one embodiment, the antigen-binding molecule comprises the heavy chain constant region and the light chain constant region of a canine IgGA molecule.

[0097] In one embodiment, the antigen-binding molecule comprises the heavy chain constant region of a canine IgGB molecule. In one embodiment, the antigen-binding molecule comprises the light chain constant region of a canine IgGB molecule. In one embodiment, the antigen-binding molecule comprises the heavy and light chain constant regions of a canine IgGB molecule.

[0098] In one embodiment, the antigen-binding molecule comprises the heavy chain constant region of a canine IgGC molecule. In one embodiment, the antigen-binding molecule comprises the light chain constant region of a canine IgGC molecule. In one embodiment, the antigen-binding molecule comprises the heavy chain constant region and the light chain constant region of a canine IgGC molecule.

[0099] In one embodiment, the antigen-binding molecule comprises the heavy chain constant region of a canine IgGD molecule. In one embodiment, the antigen-binding molecule comprises the light chain constant region of a canine IgGD molecule. In one embodiment, the antigen-binding molecule comprises the heavy chain constant region and the light chain constant region of a canine IgGD molecule. In one embodiment, the canine immunoglobulin molecule is a canine IgGA comprising, consisting of, or consisting essentially of the amino acid sequence of SEQ ID NO: 2, or an amino acid sequence having at least 80% sequence identity thereto. In one embodiment, the canine IgGA comprises, consists of, or consists essentially of the amino acid sequence of SEQ ID NO: 2. In one embodiment, the antigen-binding molecule comprises an immunoglobulin heavy chain comprising, consisting of, or consisting essentially of the amino acid sequence of SEQ ID NO: 16, or an amino acid sequence having at least 80% sequence identity thereto.

[0100] In one embodiment, the antigen-binding molecule comprises an immunoglobulin light chain comprising, consisting of, or consisting essentially of the amino acid sequence of SEQ ID NO: 17, or an amino acid sequence having at least 80% sequence identity thereto.

[0101] In one embodiment, the antigen-binding molecule comprises an immunoglobulin heavy chain comprising, consisting of, or consisting essentially of the amino acid sequence of SEQ ID NO:16.

[0102] In one embodiment, the antigen-binding molecule comprises an immunoglobulin light chain comprising, consisting of, or consisting essentially of the amino acid sequence of SEQ ID NO:17.

[0103] In one embodiment, the VH is encoded by the nucleic acid sequence of SEQ ID NO: 14. In one embodiment, the VH is encoded by the nucleic acid sequence of SEQ ID NO: 15.

[0104] In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises a heavy chain constant region of a feline immunoglobulin molecule selected from the group consisting of IgG1a, IgG1b, and IgG2. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises a light chain constant region of a feline immunoglobulin molecule selected from the group consisting of IgG1a, IgG1b, and IgG2. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises a heavy chain constant region and a light chain constant region of a feline immunoglobulin molecule selected from the group consisting of IgG1a, IgG1b, and IgG2.

[0105] In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region of a feline IgG1a molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the light chain constant region of a feline IgG1a molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region and the light chain constant region of a feline IgG1a molecule.

[0106] In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region of a feline IgG1b molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the light chain constant region of a feline IgG1b molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region and the light chain constant region of a feline IgG1b molecule.

[0107] In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region of a feline IgG2 molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the light chain constant region of a feline IgG2 molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region and the light chain constant region of a feline IgG2 molecule.

[0108] Also disclosed herein are chimeric molecules comprising an IL-31-binding molecule described herein and a heterologous moiety. In some embodiments, the heterologous moiety can be a detectable moiety, a half-life extending moiety, or a therapeutic moiety. Thus, as used herein, a "chimeric" molecule is a molecule that includes one or more unrelated types of components or that includes two or more chemically distinct regions that can be conjugated to each other, fused, linked, translated, linked via a linker, chemically synthesized, expressed from a nucleic acid sequence, etc. For example, a peptide and a nucleic acid sequence, a peptide and a detectable label, an unrelated peptide sequence, etc. In embodiments in which the chimeric molecule includes amino acid sequences of different origins, the chimeric molecule includes (1) polypeptide sequences that are not found together in nature (i.e., at least one of the amino acid sequences is heterologous with respect to at least one of the other amino acid sequences), or (2) amino acid sequences that are not naturally adjacent. For example, a "chimeric" antibody, as used herein, refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, and the remainder of the heavy and / or light chain is derived from a different source or species.

[0109] In one embodiment, the antigen-binding molecule described herein is an antibody or an IL-31-binding fragment thereof. In one embodiment, the antibody is a chimeric antibody. Examples of chimeric antibodies include antibody molecules in which the VH and VL sequences are derived from a mouse and the heavy and light chain constant regions are derived from a species other than a mouse (e.g., heavy and light chain constant regions derived from a dog, cat, or horse immunoglobulin molecule).

[0110] In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises a heavy chain constant region of a canine immunoglobulin molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises a light chain constant region of a canine immunoglobulin molecule. In a further embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises a heavy chain constant region and a light chain constant region of a canine immunoglobulin molecule.

[0111] In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises a heavy chain constant region of a canine immunoglobulin molecule selected from the group consisting of IgGA, IgGB, IgGC, and IgGD. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises a light chain constant region of a canine immunoglobulin molecule selected from the group consisting of IgGA, IgGB, IgGC, and IgGD. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises a heavy chain constant region and a light chain constant region of a canine immunoglobulin molecule selected from the group consisting of IgGA, IgGB, IgGC, and IgGD.

[0112] In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region of a canine IgGA molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the light chain constant region of a canine IgGA molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region and the light chain constant region of a canine IgGA molecule.

[0113] In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region of a canine IgGB molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the light chain constant region of a canine IgGB molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region and the light chain constant region of a canine IgGB molecule.

[0114] In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region of a canine IgGC molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the light chain constant region of a canine IgGC molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region and the light chain constant region of a canine IgGC molecule.

[0115] In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region of a canine IgGD molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the light chain constant region of a canine IgGD molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region and the light chain constant region of a canine IgGD molecule.

[0116] In one embodiment, the canine immunoglobulin molecule is canine immunoglobulin gamma heavy chain A. In one embodiment, the canine immunoglobulin gamma heavy chain A comprises, consists of, or consists essentially of the amino acid sequence of SEQ ID NO: 2, or an amino acid sequence having at least 80% sequence identity thereto. In one embodiment, the canine immunoglobulin gamma heavy chain A comprises, consists of, or consists essentially of the amino acid sequence of SEQ ID NO: 2.

[0117] In one embodiment, the chimeric antibody comprises, consists of, or consists essentially of a heavy chain comprising the amino acid sequence of SEQ ID NO: 16, or an amino acid sequence having at least 80% sequence identity thereto.

[0118] In one embodiment, the chimeric antibody comprises, consists of, or consists essentially of a light chain comprising the amino acid sequence of SEQ ID NO: 17, or an amino acid sequence having at least 80% sequence identity thereto.

[0119] In one embodiment, the chimeric antibody comprises, consists of, or consists essentially of a heavy chain comprising the amino acid sequence of SEQ ID NO:16.

[0120] In one embodiment, the chimeric antibody comprises, consists of, or consists essentially of a light chain comprising the amino acid sequence of SEQ ID NO:17.

[0121] In one embodiment, the VH is encoded by the nucleic acid sequence of SEQ ID NO: 14. In one embodiment, the VH is encoded by the nucleic acid sequence of SEQ ID NO: 15.

[0122] In another embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises a heavy chain constant region of a feline immunoglobulin molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises a light chain constant region of a feline immunoglobulin molecule. In a further embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises a heavy chain constant region and a light chain constant region of a feline immunoglobulin molecule.

[0123] In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises a heavy chain constant region of a feline immunoglobulin molecule selected from the group consisting of IgG1a, IgG1b, and IgG2. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises a light chain constant region of a feline immunoglobulin molecule selected from the group consisting of IgG1a, IgG1b, and IgG2. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises a heavy chain constant region and a light chain constant region of a feline immunoglobulin molecule selected from the group consisting of IgG1a, IgG1b, and IgG2.

[0124] In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region of a feline IgG1a molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the light chain constant region of a feline IgG1a molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region and the light chain constant region of a feline IgG1a molecule.

[0125] In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region of a feline IgG1b molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the light chain constant region of a feline IgG1b molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region and the light chain constant region of a feline IgG1b molecule.

[0126] In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region of a feline IgG2 molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the light chain constant region of a feline IgG2 molecule. In one embodiment, the chimeric antibody or IL-31-binding fragment thereof comprises the heavy chain constant region and the light chain constant region of a feline IgG2 molecule.

[0127] The present disclosure also extends to the use of modified heavy and light chain constant region sequences, for example to improve stability and serum half-life.

[0128] Suitable heavy and light chain constant region sequences, including modified sequences for non-human species (e.g., canine, feline, and equine), are well known to those skilled in the art, examples of which are described in WO 2019 / 035010, the entire contents of which are incorporated herein by reference.

[0129] Also disclosed herein is an isolated nucleic acid molecule comprising a nucleic acid sequence encoding an antigen-binding molecule described herein. In one embodiment, an isolated nucleic acid molecule is provided comprising (i) a nucleic acid sequence encoding an immunoglobulin heavy chain variable region having at least 80% sequence identity to SEQ ID NO: 12 and / or (ii) a nucleic acid sequence encoding an immunoglobulin light chain variable region having at least 80% sequence identity to SEQ ID NO: 13.

[0130] In one embodiment, the nucleic acid sequence encoding the immunoglobulin heavy chain variable region comprises the nucleic acid sequence of SEQ ID NO:14.

[0131] In another embodiment, the nucleic acid sequence encoding the immunoglobulin light chain variable region comprises the nucleic acid sequence of SEQ ID NO:15.

[0132] The terms "polynucleotide" or "nucleic acid" are used interchangeably herein and refer to a polymer of nucleotides, which may be mRNA, RNA, cRNA, cDNA, or DNA. The term typically refers to a polymeric form of nucleotides at least 10 bases in length, either ribonucleotides or deoxynucleotides, or modified forms of either type of nucleotide. The term includes single- and double-stranded forms of DNA.

[0133] Also disclosed herein are expression vectors comprising nucleic acids encoding the IL-31 binding molecules described herein.

[0134] "Vector" refers to a nucleic acid molecule, preferably a DNA molecule, derived from, for example, a plasmid, bacteriophage, or virus, into which a nucleic acid sequence can be inserted or cloned. A vector preferably contains one or more unique restriction sites and can replicate autonomously in a defined host cell, including a target cell or tissue or its progenitor cell or tissue, or can integrate into the genome of a defined host so that the cloned sequence can be reproduced. Thus, a vector can be an autonomously replicating vector, i.e., a vector that exists as an extrachromosomal entity and whose replication is independent of chromosomal replication, such as a linear or closed circular plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. A vector can include any means for ensuring autonomous replication. Alternatively, a vector can be integrated into the genome of a host cell upon introduction and replicated together with the chromosome into which it has been integrated. A vector system can include a single vector or plasmid, two or more vectors or plasmids that together contain the total DNA to be introduced into the genome of the host cell, or a transposon. The choice of vector typically depends on the compatibility of the vector with the host cell into which it will be introduced. The vector may also contain a selection marker, such as an antibiotic resistance gene, that can be used for selection of suitable transformants. Examples of such resistance genes are well known to those skilled in the art.

[0135] In one embodiment, the vector is an adeno-associated virus (AAV) vector that allows for the safe administration of an IL-31 binding molecule described herein to a subject and provides sustained expression of the IL-31 binding molecule in the subject.

[0136] Adeno-associated viruses are members of the Parvoviridae family and contain a linear, single-stranded DNA genome of less than approximately 5,000 nucleotides. For efficient replication, AAV requires co-infection with a helper virus (i.e., adenovirus or herpesvirus) or the expression of helper genes. AAV vectors used to administer therapeutic nucleic acids typically lack approximately 96% of the parent genome, leaving only the terminal repeats (ITRs), which contain recognition signals for DNA replication and packaging. This eliminates immunological or toxic side effects due to viral gene expression. Furthermore, delivery of specific AAV proteins to producer cells allows AAV vectors containing AAV ITRs to be integrated into specific regions of the cellular genome as needed (see, e.g., U.S. Patent Nos. 6,342,390 and 6,821,511). Host cells containing the integrated AAV genome do not exhibit changes in cell growth or morphology (see, e.g., U.S. Patent No. 4,797,368).

[0137] The AAV ITRs are flanked by unique coding nucleotide sequences for the nonstructural replication (Rep) proteins and the structural capsid (Cap) proteins (also known as virion proteins (VPs)). The terminal 145 nucleotides are self-complementary and organize to allow the formation of energetically stable intramolecular duplexes that form T-shaped hairpins. These hairpin structures serve as origins of viral DNA replication by serving as primers for cellular DNA polymerase complexes. The Rep genes encode the Rep proteins Rep78, Rep68, Rep52, and Rep40. Rep78 and Rep68 are transcribed from the p5 promoter, while Rep52 and Rep40 are transcribed from the p19 promoter. The Rep78 and Rep68 proteins are multifunctional DNA-binding proteins that perform helicase and nickase functions during productive replication to enable AAV terminus resolution (see, e.g., Im et al., Cell, 61:447-57 (1990)). These proteins also regulate transcription from the endogenous AAV promoter and promoters within the helper virus (see, e.g., Pereira et al., J. Virol., 71:1079-1088 (1997)). Other Rep proteins modify the function of Rep78 and Rep68. The cap gene encodes the capsid proteins VP1, VP2, and VP3. The cap gene is transcribed from the p40 promoter.

[0138] Also disclosed herein are expression constructs comprising a nucleic acid sequence encoding an IL-31 binding molecule as described herein operably linked to one or more regulatory sequences.

[0139] The term "construct" refers to a recombinant genetic molecule containing one or more isolated nucleic acid sequences from different sources. Thus, a construct is a chimeric molecule in which two or more nucleic acid sequences of different origins are assembled into a single nucleic acid molecule, and includes any construct containing (1) a nucleic acid sequence containing regulatory and coding sequences not found together in nature (i.e., at least one of the nucleotide sequences is heterologous to at least one of the other nucleotide sequences), or (2) a sequence encoding a portion of a functional RNA molecule or protein that is not naturally contiguous, or (3) a portion of a promoter that is not naturally contiguous. Exemplary constructs include any recombinant nucleic acid molecule, such as a plasmid, cosmid, virus, autonomously replicating polynucleotide molecule, phage, or linear or circular single- or double-stranded DNA or RNA nucleic acid molecule, from any source, capable of genomic integration or autonomous replication, that contains one or more operably linked nucleic acid molecules. Constructs of the invention generally contain elements necessary to direct expression of a nucleic acid sequence of interest, such as a target nucleic acid sequence or a modulator nucleic acid sequence, that are also included in the construct. Such elements may include control elements or regulatory sequences, such as a promoter, operably linked to the nucleic acid sequence of interest (to direct its transcription), and often also include a polyadenylation sequence. In certain embodiments of the present invention, the construct may be contained within a vector. In addition to the components of the construct, the vector may include, for example, one or more selectable markers, one or more origins of replication, e.g., prokaryotic and eukaryotic origins of replication, at least one multiple cloning site, and / or elements to facilitate stable integration of the construct into the genome of a host cell. Two or more constructs may be contained within a single nucleic acid molecule, such as a single vector, or may be contained within two or more separate nucleic acid molecules, such as two or more separate vectors. An "expression construct" generally includes at least one control sequence operably linked to the nucleotide sequence of interest.Thus, for example, a promoter operably associated with a nucleotide sequence to be expressed is provided in an expression construct for expression in an organism or portion thereof, including a host cell. Conventional compositions and methods for preparing and using constructs and host cells for the practice of the present invention are well known to those skilled in the art; see, for example, Molecular Cloning: A Laboratory Manual, 3rd edition Volumes 1, 2, and 3. JF Sambrook, DW Russell, and N. Irwin, Cold Spring Harbor Laboratory Press, 2000.

[0140] As used herein, the terms "control element," "control sequence," "regulatory sequence," and the like refer to nucleic acid sequences (e.g., DNA) necessary for the expression of an operably linked coding sequence in a particular host cell. Control sequences suitable for prokaryotic cells include, for example, a promoter and, optionally, cis-acting sequences such as an operator sequence and a ribosome binding site. Control sequences suitable for eukaryotic cells include transcriptional control sequences, such as promoters, polyadenylation signals, transcriptional enhancers, translational control sequences, such as translational enhancers and internal ribosome binding sites (IRES), nucleic acid sequences that modulate mRNA stability, and targeting sequences that target the product encoded by the transcribed polynucleotide to an intracellular compartment within the cell or to the extracellular environment.

[0141] Also disclosed herein are host cells containing the constructs defined herein.

[0142] The terms "host," "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," and include the primary transformed cell and its progeny, regardless of the number of passages. The progeny may not be completely identical in nucleic acid content to the parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected in the originally transformed cell are included herein. Host cells are any type of cell line that can be used to produce the antigen-binding molecules of the present invention. Host cells include cultured cells, such as cultured mammalian cells, e.g., CHO cells, BHK cells, NS0 cells, SP2 / 0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells, or hybridoma cells, yeast cells, insect cells, and plant cells, including, to name just a few, transgenic animals, transgenic plants, or cells contained in cultured plants or animal tissues. In one embodiment, the host cell is a CHO or HEK293 cell line.

[0143] Also provided are methods for producing a modified IL-31 binding molecule as described herein, such methods comprising culturing a host cell disclosed herein and recovering the IL-31 binding molecule from the host cell or culture medium.

[0144] Also disclosed herein are pharmaceutical compositions comprising an IL-31 binding molecule or vector described herein and a pharmaceutically acceptable carrier.

[0145] As described elsewhere herein, the inventors have discovered that the IL-31-binding molecules disclosed herein bind to an epitope of IL-31 that is not bound by any known IL-31 antigen-binding molecules, specifically an epitope of IL-31 that includes amino acid residues L29, Y32, Q33, and P40 of SEQ ID NO: 1. Identification of this epitope of IL-31 advantageously allows the identified epitope, or a mimotope thereof, to be used as an immunogenic composition to induce an immune response when the immunogenic composition is administered to a subject. Thus, one aspect disclosed herein provides an immunogenic composition capable of eliciting an immune response against IL-31, the composition comprising: (i) an immunogen comprising a B cell epitope of IL-31; and (ii) a pharmaceutically acceptable carrier, wherein the B cell epitope comprises an amino acid sequence corresponding to amino acid positions 29-40 of SEQ ID NO: 1, or an amino acid sequence having at least 80% sequence identity thereto; and the immunogen does not comprise the amino acid sequence of a native IL-31 molecule. In one embodiment, the immunogen consists of an amino acid sequence corresponding to amino acid positions 29-40 of SEQ ID NO: 1, or an amino acid sequence having at least 80% sequence identity thereto. In another embodiment, the immunogen consists of an amino acid sequence corresponding to amino acid positions 29-40 of SEQ ID NO: 1. As stated elsewhere herein, reference to "at least 80% sequence identity" includes 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with a reference sequence, for example, after optimal alignment or best fit analysis.

[0146] "Pharmaceutically acceptable carrier" means a pharmaceutical vehicle composed of a material that is not biologically or otherwise undesirable, i.e., the material may be administered to a subject together with a selected active agent without causing any or substantial adverse reactions. Carriers may include excipients and other additives, such as diluents, detergents, colorants, wetting or emulsifying agents, pH buffering agents, preservatives, and the like.

[0147] Representative pharmaceutically acceptable carriers, as known to those skilled in the art (see, e.g., Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329, incorporated herein by reference), include any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, and similar materials, and combinations thereof. Except insofar as any conventional carrier is incompatible with the active ingredient(s), its use in the pharmaceutical compositions is contemplated.

[0148] Pharmaceutical compositions can be in various forms. These include, for example, liquid, semi-solid, and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, liposomes, and suppositories. The preferred form depends on the intended mode of administration and therapeutic application. Suitable pharmaceutical compositions can be administered intravenously, subcutaneously, or intramuscularly. In some embodiments, the composition is in the form of an injectable or infusible solution. The preferred mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular). In certain embodiments, the pharmaceutical composition is administered by intravenous infusion or injection. In other embodiments, the pharmaceutical composition is administered by intramuscular or subcutaneous injection.

[0149] As used herein, the phrases "parenteral administration" and "administered parenterally" refer to modes of administration other than enteral and topical administration, usually by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion.

[0150] Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions, or suspensions, including saline and buffered media. In the present invention, pharmaceutically acceptable carriers include, but are not limited to, 0.01-0.1 M, preferably 0.05 M, phosphate buffer or 0.8% saline. Other common parenteral vehicles include sodium phosphate solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's solution, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like. Preservatives and other additives, such as antimicrobials, antioxidants, chelating agents, and inert gases, may also be present.

[0151] More specifically, pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In such cases, the composition must be sterile and fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage, and preferably preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin and / or by controlling the required particle size. In certain embodiments, the agents of the present disclosure can be conjugated to a vehicle for cellular delivery. In these embodiments, the agent can be encapsulated in an appropriate vehicle to aid in delivery of the agent to target cells, enhance the agent's stability, or minimize potential toxicity. As will be understood by those skilled in the art, various vehicles are suitable for delivering the agents of the present disclosure. Non-limiting examples of suitable structured fluid delivery systems may include nanoparticles, liposomes, microemulsions, micelles, dendrimers, and other phospholipid-containing systems. Methods for incorporating the agents of the present disclosure into delivery vehicles are known in the art. Although various embodiments are presented below, it will be understood that other methods known in the art for incorporating the antigen-binding molecules described herein into delivery vehicles are contemplated.

[0152] The administration regimen is adjusted to provide the optimal desired response (e.g., therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. The antigen-binding molecules of the present disclosure can be administered on multiple occasions. The interval between single doses can be daily, weekly, monthly, or yearly. The intervals can also be irregular, as indicated by measuring the blood level of the modified polypeptide or antigen in the patient. Alternatively, the antigen-binding molecule can be administered as a sustained-release formulation, in which case less frequent administration is required. The dosage and frequency vary depending on the half-life of the polypeptide in the patient.

[0153] For ease of administration and uniformity of dosage, it may be advantageous to formulate compositions in unit dosage form.As used herein, unit dosage form refers to a physically separate unit that is suitable as a unit dosage for the subject to be treated.Each unit contains a predetermined amount of active compound calculated to produce desired therapeutic effect in association with the required pharmaceutically acceptable carrier.The specifications of the unit dosage form of the present invention are determined by and directly depend on (a) the inherent characteristics of active compound and the specific therapeutic effect to be achieved, and (b) the inherent limitations of the technology of compounding such active compound for treating the sensitivity in individuals.

[0154] The dosage and treatment regimen of the antigen-binding molecule can be determined by one skilled in the art. In a specific embodiment, the antigen-binding molecule is administered by injection (e.g., subcutaneously or intravenously) at a dose of about 0.01 to 40 mg / kg, e.g., 0.01 to 0.1 mg / kg, e.g., about 0.1 to 1 mg / kg, about 1 to 5 mg / kg, about 5 to 25 mg / kg, about 10 to 40 mg / kg, or about 0.4 mg / kg. The administration schedule can vary, for example, from once a week to once every 2, 3, or 4 weeks. In one embodiment, the antigen-binding molecule is administered every other week at a dose of about 10 to 20 mg / kg. An exemplary, non-limiting range for an effective amount of an antigen-binding molecule of the present disclosure is 0.01 to 5 mg / kg, more suitably 0.03 to 2 mg / kg.

[0155] It should be noted that dosage value can vary according to the type and severity of the condition to be alleviated.It should be further understood that for any specific subject, specific dosage regimen should be adjusted over time according to individual need and the professional judgment of the person who administers or supervises the administration of composition, and the dosage ranges described herein are merely illustrative and are not intended to limit the scope or implementation of the claimed compositions.

[0156] The pharmaceutical compositions of the present invention may comprise an effective amount of an agent (i.e., an IL-31-binding molecule) disclosed herein. The effective amount may be a "therapeutically effective amount" or a "prophylactically effective amount." A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of an agent may vary depending on factors such as the disease state, the age, sex, and weight of the individual, and the ability of the agent to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or adverse effects of the agent are outweighed by the therapeutically beneficial effects. Alternatively, this property of a composition can be assessed by assays known to those skilled in the art, such as by examining the ability of a compound to inhibit in vitro.

[0157] In contrast, a "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount is less than the therapeutically effective amount.

[0158] Also disclosed herein are methods for treating or preventing conditions associated with increased expression and / or activity of IL-31, the methods comprising administering to a subject in need thereof an antigen-binding molecule, vector, or pharmaceutical composition described herein.

[0159] As used herein, the term "treating" may refer to (1) delaying the appearance of one or more symptoms of a condition; (2) inhibiting the onset of a condition or one or more symptoms of a condition; (3) alleviating a condition, i.e., causing a regression of a condition or at least one or more symptoms of a condition; and / or (4) causing a decrease in the severity of a condition or one or more symptoms of a condition.

[0160] The terms "treating," "treatment," and the like are used interchangeably herein to mean to alleviate, reduce, alleviate, ameliorate, or otherwise inhibit a condition, including one or more symptoms of the condition. The terms "prevent," "preventing," "prophylaxis," "prophylactic," "preventative," and the like are used interchangeably herein to mean to prevent or delay the onset of a condition or the risk of developing a condition.

[0161] The terms "treating," "treatment," and the like also include alleviating, reducing, alleviating, ameliorating, or otherwise inhibiting the effects of a condition for at least a period of time. It should also be understood that the terms "treating," "treatment," and the like do not imply that a condition or its symptoms will be permanently alleviated, reduced, alleviated, ameliorated, or otherwise inhibited, and thus encompass temporary alleviation, reduction, alleviation, amelioration, or other inhibition of a condition or its symptoms.

[0162] The terms "subject," "patient," "host," or "individual," used interchangeably herein, refer to any animal in need of treatment. Subjects typically include non-human subjects, including, but not limited to, mammals, birds, and fish, and suitably include domestic, farm, zoo, and wild animals, such as cows, pigs, horses, goats, sheep, or other ungulates, dogs, cats, chickens, ducks, non-human primates, guinea pigs, rabbits, ferrets, rats, hamsters, and mice. In one embodiment, the subject is selected from the group consisting of dogs, cats, and horses. In one embodiment, the subject is a dog. In one embodiment, the subject is a cat. In one embodiment, the subject is a horse.

[0163] Conditions associated with abnormal (e.g., increased) levels and / or abnormal (e.g., increased) activity of IL-31 are well known to those of skill in the art and include, for example, chronic pruritic skin disorders such as atopic eczema, as well as non-dermatological conditions such as allergic asthma and rhinitis, inflammatory bowel disease, malignancies (e.g., cancer), and osteoporosis.

[0164] In one embodiment, the condition associated with increased expression and / or activity of IL-31 is selected from the group consisting of pruritus and dermatitis. In one embodiment, the condition is atopic dermatitis. In one embodiment, the condition is pruritus.

[0165] Also provided herein is an antigen-binding molecule or vector described herein for use in treating, inhibiting, or ameliorating a condition associated with increased expression and / or activity of IL-31 in a subject.

[0166] Also provided herein is the use of an IL-31-binding molecule or vector described herein in the manufacture of a medicament for treating, inhibiting, or ameliorating a condition associated with an abnormal (e.g., increased) level and / or abnormal (e.g., increased) activity of IL-31, as described herein, in a subject in need thereof.

[0167] Also disclosed herein is a method for treating or preventing a condition caused by, associated with, or resulting from increased expression of or increased sensitivity to IL-31 in a subject in need thereof, the method comprising administering an IL-31-binding molecule or vector described herein to a canine subject in need thereof.

[0168] Also disclosed herein is an IL-31-binding molecule, or vector, or pharmaceutical composition described herein for use in treating a condition caused by, associated with, or resulting from increased expression of or increased sensitivity to IL-31 in a subject.

[0169] The present disclosure also extends to the use of an IL-31 binding molecule or vector described herein in the manufacture of a medicament for the treatment of a condition caused by, associated with, or resulting from increased expression of or increased sensitivity to IL-31 in a subject.

[0170] The present disclosure also extends to a method for treating or preventing tumors whose growth is induced by IL-31 and conditions associated therewith, comprising administering to a subject in need thereof an IL-31-binding molecule, or vector, or pharmaceutical composition described herein.

[0171] Also provided herein is an IL-31-binding molecule, or vector, or pharmaceutical composition described herein for use in treating or preventing IL-31-induced growth of tumors and conditions associated therewith in a subject in need thereof.

[0172] The present disclosure also extends to the use of an IL-31-binding molecule or vector described herein in the manufacture of a medicament for the treatment or prevention of IL-31-induced growth tumors and conditions related thereto in a subject in need thereof.

[0173] The present disclosure also extends to kits comprising the IL-31 binding molecules or vectors or pharmaceutical compositions described herein.

[0174] Also disclosed herein is the use of an IL-31 binding molecule or vector described herein for detecting IL-31 in a sample.

[0175] As used herein, "and / or" refers to and includes any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (or).

[0176] As used in this application, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. For example, the term "an agent" includes a plurality of agents, including mixtures thereof.

[0177] "About" means an amount, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by about 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1% of the reference amount, level, value, number, frequency, percentage, dimension, size, amount, weight or length.

[0178] Throughout this specification and the following description, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", are understood to mean the inclusion of a stated integer or step or group of integers or steps, but not the exclusion of any other integer or step or group of integers or steps.

[0179] Reference herein to any prior publication (or information derived therefrom) or any known matter is not, and should not be construed as, an acknowledgement, admission, or any form of suggestion that the prior publication (or information derived therefrom) or known matter forms part of the common general knowledge in the field of endeavor to which this specification pertains.

[0180] Those skilled in the art will understand that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications that are within its spirit and scope. The invention also includes all of the steps, features, compositions and compounds referred to or indicated herein, individually or collectively, and includes any and all combinations of any two or more of the steps or features.

[0181] Specific embodiments of the present invention will now be described with reference to the following examples, which are intended for illustrative purposes only and are not intended to limit the scope of the generality set forth above. [Example]

[0182] Example 1: Generation of a mouse monoclonal antibody that recognizes canine interleukin-31 (IL-31) Recombinant canine IL-31 (ProSpec-Tany, Israel) produced in Sf9 baculovirus cells containing 142 amino acids (amino acid residues 24 to 159 of accession number NP_001159386 ; SEQ ID NO: 1 ) fused at the C-terminus to a 6-amino acid His-Tag was used as an immunogen to generate antibodies in Balb / c mice. Canine IL-31 protein [ka]

[0183] Antibody titers from immunized mice were determined using an enzyme-linked immunosorbent assay (ELISA). Canine IL-31 (100 ng / well) was immobilized on a polystyrene microplate as a capture antigen and blocked with PBS / 0.05% Tween® 20 / 1% BSA. The coated wells were incubated with monoclonal antibodies (mAbs) diluted in PBS / 0.05% Tween® 20 / 1% BSA (100 μl / well) for 1 hour at room temperature. A standard curve was established using mAb concentrations ranging from 1000 ng / ml to 1.37 ng / ml. After washing, plates were incubated with 1 / 10,000 diluted alkaline phosphatase-conjugated AffiniPure goat anti-mouse IgG (subclasses 1+2a+2b+3), Fcg fragment-specific (Jackson Immuno Research Laboratories, Inc.) or alkaline phosphatase-conjugated rabbit anti-dog IgG (whole molecule; Sigma) in PBS / 0.05% Tween® 20 / 1% BSA. Plates were washed with PBS / 0.05% Tween® 20 and developed by the addition of 3,3',5,5'-tetramethylbenzidine (TMB) substrate. Color development was stopped by adding 100 μl of 2 M H2SO4, and the absorbance of each well was determined at 450 nm.

[0184] Spleens from three mice immunized with canine IL-31 protein (SEQ ID NO: 1) were isolated and used individually for hybridoma generation using standard techniques (see, e.g., Albitar (2007; Methods in Molecular Biology; Monoclonal Antibodies Volume 378 || Development and Characterization of Mouse Hybridomas, 10.1007 / 978-1-59745-323-3 (Chapter 1)). After fusion, hybridomas were plated in multiwell plates. 6000 wells were screened for binding to canine IL-31 using a microarray ELISA format.

[0185] Among the candidates identified during screening, one hybridoma showed good binding to canine IL-31 and inhibition of canine IL-31 activity, and was subsequently cloned and sequenced (clone designation RA4.D2).

[0186] The sequences of the heavy chain variable region (VH) and light chain variable region (VL) of the subclones for RA4.D2 were obtained by PCR amplification of the VH and VL regions from cDNA obtained from the hybridoma. Analysis of the VH and VL gene sequences was performed using the IMGT / V-Quest program (International Immunogenetics Information System; http: / / www.imgt.org / IMGT_vquest / vquest).

[0187] To generate the chimeric antibody chRA4, the heavy chain variable sequence of the murine monoclonal antibody RA4 was fused to the constant region of the canine immunoglobulin gamma heavy chain A of SEQ ID NO: 2 (corresponding to amino acid positions 138-468 of GenBank: AAL35301), and the light chain variable sequence was fused to the constant region of the canine immunoglobulin gamma heavy chain A of IGKC from IMGT as shown below. * fused to the constant region corresponding to the 01 allele (accession number IMGT000067): canine heavy chain constant region [ka] Canine kappa light chain constant region [ka] [Table 1A] [Table 1B] Amino acid sequences of the heavy (VH) and light (VL) chain variable regions of mouse monoclonal antibody RA4.D2 (CDR sequences (identified by IMGT) are underlined) RA4_VH [ka] RA4_VL [ka] Nucleotide sequences encoding the heavy chain (VH) and light chain (VL) variable regions of the murine monoclonal antibody RA4.D2. RA4_Heavy chain variable region (VH) [ka] RA4_Light chain variable region (VL); (κ light chain) [ka] Amino acid sequences of the heavy chain (HC) and light chain (LC) regions of the chimeric RA4.D2 antibody chRA4_HC [ka] chRA4_LC [ka]

[0188] To produce the caninized RA4 monoclonal antibody, the framework regions of the heavy and light chain variable sequences of the mouse monoclonal antibody RA4 were replaced with canine heavy and light chain framework regions. Canine antibody sequences were searched for comparison with the mouse heavy and light chain variable domains using the BLAST search algorithm and candidate canine variable domains selected from the top 200 BLAST results. Top candidates were selected based on a combination of framework homology that maintained key framework residues and canonical loop structures.

[0189] The amino acid sequences of the caninized RA4 heavy and light chain variable regions are shown below: RA4 caninized heavy chain VHC5 [ka] VHC6 [ka] RA4 caninized light chain VLC6 [ka] [Table 2-1] [Table 2-2]

[0190] To produce the felineized RA4 monoclonal antibody, the framework regions of the heavy and light chain variable sequences of the mouse monoclonal antibody RA4 are replaced with feline heavy and light chain framework region sequences. A BLAST search algorithm is used to search feline antibody sequences for comparison with the mouse heavy and light chain variable domains, and candidate feline variable domains are selected from the top 200 BLAST results. Top candidates are selected based on a combination of framework homology that maintains key framework residues and canonical loop structures. [Table 3]

[0191] Example 2: Determination of the binding of monoclonal antibody RA4 to canine IL-31, feline IL-31 and canine IL-31 variants To assess whether murine monoclonal antibody RA4 bound to the regions of canine IL-31 targeted by the previously published anti-IL-31 antibody M14 (described in U.S. Pat. No. 10,093,731 B2) and mAb 34D03 (described in U.S. Pat. No. 8,790,651 B2), two mutant canine IL-31 proteins were generated with alanine substitutions introduced at (i) amino acid positions 76, 77, 80, 81, and 84 of SEQ ID NO: 1 (canine IL-31 variant 1; SEQ ID NO: 62) and (ii) amino acid positions 13, 15, 20, and 26 of SEQ ID NO: 1 (canine IL-31 variant 2; SEQ ID NO: 63). The amino acid positions of canine IL-31 variants 1 and 2 targeted for alanine substitutions were previously determined to be involved in the binding of 34D03 and M14 to canine IL-31, respectively.

[0192] The amino acid sequences of canine IL-31 variants 1 and 2 and feline IL-31 proteins are provided below: Canine IL-31 variant 1 (alanine substitutions are identified by bold and underlined text) [ka] Canine IL-31 variant 2 (alanine substitutions are identified by bold and underlined text) [ka] Feline IL-31 [ka]

[0193] Purified mouse RA4 and recombinant chimeric RA4 mAb were analyzed for binding to canine IL-31 by ELISA as described above. As shown in Figure 1, chimeric antibody RA4 (chRA4) bound to canine IL-31 in a dose-dependent manner, as determined by ELISA. Consistent with these binding data, chRA4 was shown to neutralize canine IL-31 activity in vitro, as evidenced by inhibition of canine IL-31-induced STAT-3 phosphorylation in canine DH82 cells (Figure 2). The ability of RA4 mAb to neutralize IL-31-mediated pSTAT3 signaling in a canine monocytic cell line was assessed as follows: canine DH-82 cells were pretreated with 10 ng / mL canine gamma interferon for 24 hours and then serum-starved for 2 hours. Cell supernatants were incubated with canine IL-31 (160 ng / mL) for 60 minutes. The RA4 / IL-31 mixture was then added to the cells for 5 min, and STAT phosphorylation was assessed using pSTAT3 ELISA (STAT-3(Phospho)[pY705]Multispecies ELISA kit, Invitrogen).

[0194] To assess whether RA4 mAb bound to the region of canine IL-31 targeted by the previously published anti-IL-31 antibodies M14 and 34D03, two mutant canine IL-31 proteins were generated with alanine substitutions introduced at (i) amino acid positions 76, 77, 80, 81, and 84 of SEQ ID NO:1 (canine IL-31 variant 1; SEQ ID NO:62) and (ii) amino acid positions 13, 15, 20, and 26 of SEQ ID NO:1 (canine IL-31 variant 2; SEQ ID NO:63).

[0195] As shown in Figure 3, RA4 bound to both canine IL-31, feline IL-31 (SEQ ID NO: 64), and the canine IL-31 mutant proteins Mutant 1 (SEQ ID NO: 62) and Mutant 2 (SEQ ID NO: 63). M14 bound to canine IL-31 and canine IL-31 Mutant 1, but did not show significant binding to canine IL-31 Mutant 2. M14 shows minimal binding to feline IL-31. 34D03 bound to canine IL-31 and, to a lesser extent, feline IL-31, but did not show significant binding to either Mutant 1 or Mutant 2. RA4 did not bind to human IL-31 in these studies.

[0196] Example 3: Identification of the binding epitope on canine interleukin-31 (caIL-31) for anti-caIL-31 mAb clone RA4 As noted above in Example 2, the murine RA4 mAb does not bind to key residues involved in the binding of the anti-canine IL-31 mAbs M14 and 34D03.

[0197] To define the region of canine IL-31 that binds to RA4, a number of chimeric and truncated canine IL-31 peptides were generated, as shown below (see also Figure 4A). The human IL-31-derived amino acid sequence is identified by underlined text: Canine IL-31 (SEQ ID NO: 1) [ka] Canine / human chIL-31_c123_h4 [ka] Canine / human chIL-31_c12_h34 [ka] Canine / human chIL-31_c1_h234 [ka]

[0198] The amino acid sequence of the canine IL-31 protein identified in Figure 5 is as follows: Canine IL-31 N-terminus [ka] Canine IL-31 N-terminus 201 [ka] Canine IL-31 N-terminus 202 [ka] Canine IL-31 N-terminus 203 [ka] Canine IL-31 N-terminus 204 [ka]

[0199] The amino acid sequence of the canine IL-31 protein identified in Figure 7 is as follows: Canine IL-31 [ka] Canine IL-31_4xMUT_combo [ka] Canine IL-31_L29A [ka] Canine IL-31_Y32A [ka] Canine IL-31_Q33A [ka] Canine IL-31_P40A [ka]

[0200] Binding to various IL-31 proteins and peptides was assessed by ELISA. IL-31 protein or peptide (100 ng / well) was immobilized on a polystyrene microplate as a capture antigen. The wells were blocked with PBS / 0.05% Tween® 20 / 1% BSA. The coated wells were incubated with anti-IL-31 mAb diluted in PBS / 0.05% Tween® 20 / 1% BSA (100 μl / well) for 1 hour at room temperature. After washing, the plates were incubated with 1 / 10,000 diluted alkaline phosphatase-conjugated rabbit anti-dog IgG (whole molecule) (Sigma) in PBS / 0.05% Tween® 20 / 1% BSA. The plates were washed with PBS / 0.05% Tween® 20 and developed by adding TMB substrate. Color development was stopped by adding 100 ul ELISA stop solution (Invitrogen) and the absorbance of each well was determined at an optical density (OD) of 450 nm.

[0201] As shown in Figure 4B, RA4 mAb binds to a canine / human IL-31 chimeric protein containing the first 49 amino acids of canine IL-31 (SEQ ID NO: 1) incorporating IL-31 helix A. Substitution of the canine sequences for helices B, C, and D with human sequences did not abolish binding, demonstrating that the epitope of RA4 mAb resides in the N-terminal region of canine IL-31.

[0202] To further define the epitope of RA4 mAb, overlapping 20-amino acid peptides were generated (Figure 5A). As shown by the ELISA data in Figure 5B, RA4 mAb binds to a peptide containing the first 50 amino acids of canine IL-31 and peptide 3, which contains amino acid residues 30–40 of mature canine IL-31. The epitope bound by RA4 mAb is distinct from the epitopes targeted by the anti-canine IL-31 antibodies M14 and 34D03. Consistent with the data in Figure 3, 34D03 does not appear to bind to the N-terminal region of canine IL-31, suggesting that the epitope bound by 34D03 is found in helix B / C. In contrast, M14 bound only to peptide 1, which contains amino acid residues 1–20 of canine IL-31. These data indicate that RA4 mAb binds to a unique epitope of canine IL-31 that has not previously been described for M14 and 34D03.

[0203] An alanine scanning library of the region encompassing amino acid residues 18-42 of SEQ ID NO:1 was generated, consisting of 25 peptides, each with a single alanine mutation at a different residue (IILELQPLSRGLLEDYQKKETGVPES; SEQ ID NO:79). Binding of RA4 mAb to each peptide was determined by ELISA, as described above.

[0204] As shown in Figure 6, where binding to each peptide is expressed as a percentage of binding to the first peptide in the series, the data demonstrate four critical residues that, when substituted with alanine, severely affected RA4 binding to canine IL-31. The alanine mutations corresponding to L29A, Y32A, Q33A, and P40A all reduced binding to the canine IL-31 peptide to less than 15% of the first peptide. Three additional residues were also shown to be important for binding to canine IL-31; when substituted with alanine residues, binding was reduced to less than 50% (K35A, V39A, and S42A).

[0205] The unique epitope targeted by the RA4 mAb was confirmed by assessing its binding to full-length canine IL-31 protein containing each of the four key residues identified above substituted with alanine, as well as a version containing all four residues substituted with alanine in combination. Histidine-tagged proteins were produced in mammalian cells after transient transfection and purified via nickel affinity chromatography. Binding of RA4 mAb and M14 mAb to each protein was determined by ELISA, as described above. As shown in Figure 7, the chimeric RA4 mAb was able to bind to all proteins with single amino acid alanine substitutions, compared to binding to wild-type canine IL-31 protein (Figure 7A). When all four residues (L29, Y32, Q33, and P40) were substituted with alanine in combination, no binding to canine IL-31 was detected. In contrast, M14 mAb bound equally well to all mutant proteins and wild-type canine IL-31 protein. These data indicate that the epitope comprising amino acid residues L29, Y32, Q33 and P40 of canine Il-31 (SEQ ID NO: 1) is unique to the RA4 mAb.

Claims

1. An antigen-binding molecule that specifically binds to interleukin-31 (IL-31), comprising: (i) an immunoglobulin heavy chain variable domain (VH), comprising: (a) a complementarity determining region 1 (VH CDR1) comprising or consisting of the amino acid sequence of SEQ ID NO:6, or an amino acid sequence having at least 80% sequence identity thereto; (b) a VH CDR2 comprising or consisting of an amino acid sequence of SEQ ID NO:7, or an amino acid sequence having at least 80% sequence identity thereto; (c) a VH CDR3 comprising or consisting of the amino acid sequence of SEQ ID NO:8 or an amino acid sequence having at least 80% sequence identity thereto; an immunoglobulin VH comprising: (ii) an immunoglobulin light chain variable domain (VL), comprising: (a) a complementarity determining region 1 (VL CDR1) comprising or consisting of the amino acid sequence of SEQ ID NO:9, or an amino acid sequence having at least 80% sequence identity thereto; (b) a VL CDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 10, or an amino acid sequence having at least 80% sequence identity thereto; (c) a VL CDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 11 or an amino acid sequence having at least 80% sequence identity thereto; Immunoglobulin VL comprising wherein the amino acid sequence of the CDR is based on the IMGT numbering system.

2. An antigen-binding molecule that specifically binds to an epitope of canine IL-31 comprising amino acid residues L29, Y32, Q33 and P40 of SEQ ID NO:

1.

3. An antigen-binding molecule that competes with the antigen-binding molecule of claim 1 for binding to canine IL-31 of SEQ ID NO:

1.

4. The antigen-binding molecule of claim 1, which does not compete for binding to IL-31 with (i) an IL-31-binding molecule that specifically binds to a region of IL-31 corresponding to amino acid positions 13, 15, 20, and 26 of SEQ ID NO:1, or (ii) an IL-31-binding molecule that specifically binds to a region of IL-31 corresponding to amino acid positions 76, 77, 80, 81, and 84 of SEQ ID NO:

1.

5. The antigen-binding molecule of claim 1 , wherein the molecule is a caninized, felineized, or equine-ized antigen-binding molecule.

6. The caninized antigen-binding molecule comprises: (i) a heavy chain variable domain (VH) comprising: (a) a heavy chain variable domain framework region 1 (VHFR1) amino acid sequence having at least 80% sequence identity to a VHFR1 amino acid sequence selected from the group consisting of SEQ ID NOs: 18, 22, 26, 30, and 34; (b) a VHFR2 amino acid sequence having at least 80% sequence identity to a VHFR2 amino acid sequence selected from the group consisting of SEQ ID NOs: 19, 23, 27, 31, and 35; (c) a VHFR3 amino acid sequence having at least 80% sequence identity to a VHFR3 amino acid sequence selected from the group consisting of SEQ ID NOs: 20, 24, 27, 32, and 36; and (d) a VHFR4 amino acid sequence having at least 80% sequence identity to a VHFR4 amino acid sequence selected from the group consisting of SEQ ID NOs: 21, 25, 28, 33, and 37; and / or (ii) a light chain variable domain (VL) comprising: (a) a heavy chain variable domain framework region 1 (VLFR1) amino acid sequence having at least 80% sequence identity to a VLFR1 amino acid sequence selected from the group consisting of SEQ ID NOs: 38, 42, 46, and 50; (b) a VLFR2 amino acid sequence having at least 80% sequence identity to a VLFR2 amino acid sequence selected from the group consisting of SEQ ID NOs: 39, 43, 47, and 51; (c) a VLFR3 amino acid sequence having at least 80% sequence identity to a VLFR3 amino acid sequence selected from the group consisting of SEQ ID NOs: 40, 44, 48, and 52; and (d) a VLFR4 amino acid sequence having at least 80% sequence identity to a VHFR4 amino acid sequence selected from the group consisting of SEQ ID NOs: 41, 45, 49, and 53. Contains, or The caninized antigen-binding molecule comprises: (i) a heavy chain variable domain (VH) comprising: (a) a heavy chain variable domain framework region 1 (VHFR1) amino acid sequence having at least 80% sequence identity to the VHFR1 amino acid sequence of SEQ ID NO: 81 or SEQ ID NO: 85; (b) a VHFR2 amino acid sequence having at least 80% sequence identity to the VHFR2 amino acid sequence of SEQ ID NO: 82 or SEQ ID NO: 86; (c) a VHFR3 amino acid sequence having at least 80% sequence identity to the VHFR3 amino acid sequence of SEQ ID NO: 83 or SEQ ID NO: 87, and (d) a VHFR4 amino acid sequence having at least 80% sequence identity to the VHFR4 amino acid sequence of SEQ ID NO: 84 or SEQ ID NO: 88; and / or (ii) a light chain variable domain (VL) comprising: (a) a heavy chain variable domain framework region 1 (VLFR1) amino acid sequence having at least 80% sequence identity to the VLFR1 amino acid sequence of SEQ ID NO:89; (b) a VLFR2 amino acid sequence having at least 80% sequence identity to the VLFR2 amino acid sequence of SEQ ID NO: 90; (c) a VLFR3 amino acid sequence having at least 80% sequence identity to the VLFR3 amino acid sequence of SEQ ID NO: 91; and (d) a VLFR4 amino acid sequence having at least 80% sequence identity to the VHFR4 amino acid sequence of SEQ ID NO:

92. The antigen-binding molecule of claim 5 .

7. the heavy chain variable domain (VH) comprises an amino acid sequence having at least 80% sequence identity to the VH amino acid sequence of SEQ ID NO: 99 or SEQ ID NO: 100; and / or The antigen-binding molecule of claim 6, wherein the light chain variable domain (VL) comprises an amino acid sequence having at least 80% sequence identity to the VL amino acid sequence of SEQ ID NO:

101.

8. The fetinized antigen-binding molecule comprises: (i) a heavy chain variable domain (VH) comprising: (a) a heavy chain variable domain framework region 1 (VHFR1) amino acid sequence having at least 80% sequence identity to the VHFR1 amino acid sequence of SEQ ID NO:54; (b) a VHFR2 amino acid sequence having at least 80% sequence identity to the VHFR2 amino acid sequence of SEQ ID NO:55; (c) a VHFR3 amino acid sequence having at least 80% sequence identity to the VHFR3 amino acid sequence of SEQ ID NO:56; and (d) a VHFR4 amino acid sequence having at least 80% sequence identity to the VHFR4 amino acid sequence of SEQ ID NO:57; and / or (ii) a light chain variable domain (VL) comprising: (a) a light chain variable domain framework region 1 (VLFR1) amino acid sequence having at least 80% sequence identity to the VLFR1 amino acid sequence of SEQ ID NO:58; (b) a VLFR2 amino acid sequence having at least 80% sequence identity to the VLFR2 amino acid sequence of SEQ ID NO:59; (c) a VLFR3 amino acid sequence having at least 80% sequence identity to the VLFR3 amino acid sequence of SEQ ID NO: 60; and (d) a VLFR4 amino acid sequence having at least 80% sequence identity to the VHFR4 amino acid sequence of SEQ ID NO:

61. The antigen-binding molecule of claim 5 .

9. The antigen-binding molecule of claim 1, wherein the antigen-binding molecule is an antibody or an IL-31-binding fragment thereof.

10. The antigen-binding molecule of claim 9, wherein the IL-31-binding fragment is selected from the group consisting of a Fab fragment, a scFab, a Fab', a single-chain variable fragment (scFv), and a one-arm antibody.

11. The antigen-binding molecule of claim 1 , wherein the antigen-binding molecule comprises a heavy chain constant region and / or a light chain constant region of a canine, feline or equine immunoglobulin molecule.

12. The antigen-binding molecule of claim 11, wherein the feline immunoglobulin molecule is selected from the group consisting of IgG1a, IgG1b and IgG2.

13. The antigen-binding molecule of claim 11, wherein the canine immunoglobulin molecule is selected from the group consisting of IgGA, IgGB, IgGC and IgGD.

14. The antigen-binding molecule of claim 13, wherein the canine immunoglobulin molecule comprises an amino acid sequence of SEQ ID NO: 2, or an amino acid sequence having at least 80% sequence identity thereto.

15. the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 16 or an amino acid sequence having at least 80% sequence identity thereto; and / or The antigen-binding molecule of claim 13, wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 17 or an amino acid sequence having at least 80% sequence identity thereto.

16. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the antigen-binding molecule of claim 1.

17. 17. An expression construct comprising the nucleic acid sequence of claim 16.

18. A host cell comprising the expression construct of claim 17.

19. A vector comprising a nucleic acid sequence encoding the antigen-binding molecule of claim 1.

20. The vector of claim 19, wherein the vector is an AAV vector.

21. A pharmaceutical composition comprising the antigen-binding molecule of claim 1 and a pharma- ceutical acceptable carrier.

22. A kit comprising the antigen-binding molecule of claim 1.

23. A pharmaceutical composition for treating or preventing a condition associated with increased expression and / or activity of IL-31 in a subject in need thereof, the pharmaceutical composition comprising an antigen-binding molecule according to claim 1.

24. The pharmaceutical composition of claim 23, wherein the condition associated with increased expression and / or activity of IL-31 is selected from the group consisting of pruritis and atopic dermatitis.

25. A pharmaceutical composition for treating or preventing a tumor whose proliferation is induced by IL-31 and a condition related thereto, the pharmaceutical composition comprising an antigen-binding molecule described in claim 1.

26. 24. The pharmaceutical composition of claim 23, wherein the subject is selected from the group consisting of dogs, cats and horses.

27. 1. An immunogenic composition capable of eliciting an immune response against IL-31, said composition comprising: (i) an immunogen comprising a B cell epitope of IL-31; and (ii) a pharma- ceutically acceptable carrier, wherein said B cell epitope comprises or consists of an amino acid sequence corresponding to amino acid positions 29-40 of SEQ ID NO:1, or an amino acid sequence having at least 80% sequence identity thereto, and wherein said immunogen does not comprise the amino acid sequence of a native IL-31 molecule.